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Summary
Aortic pathology can have devastating consequences with significant morbidity and 
mortality. Marfan syndrome patients have a profound predisposition to develop aortic 
root pathology and can develop complications of aortic root pathology such as aneurysm 
of the aorta (especially the aortic root), aortic dissection and aortic valve regurgitation. 
Recent advances in understanding the pathophysiology of the consequences of fibrillin-1 
deficiency in Marfan syndrome and the development of murine models of this condition 
have opened up the possibility for translational research to be conducted in this area. 
Potential pharmacological treatments can now be extensively researched prior to clinical 
trials.
Pravastatin, a 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor has 
been shown to have a beneficial effect on atherosclerosis via “pleiotropic,” or non­
cholesterol related, anti-inflammatory mechanisms. These mechanisms may have a 
beneficial effect in aortic root pathology in Marfan syndrome.
The first aim of this research was to establish a natural history of aortic root pathology in 
Marfan syndrome and to study multiple aspects of aortic root pathology to gain an insight 
into the pathophysiology of the disease. The second aim was to compare the efficacy and 
mechanism of potential pharmacological treatments to attenuate aortic root pathology in 
Marfan syndrome, Pravastatin, Losartan and Doxycycline. The third aim was to optimise 
the dose and timing of administration of Pravastatin for aortic root pathology in Marfan 
syndrome. These aims were studied in a murine model of Marfan syndrome.
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The results obtained demonstrate that Pravastatin is equipotent to Losartan in attenuation 
of aortic root dilatation in a murine model of Marfan syndrome. Doxycycline’s 
performance was inferior to both Pravastatin and Losartan in attenuation of aortic root 
pathology.
This research provides a basis for further study into the mechanisms of aortic pathology. 
It also provides evidence for a novel potential treatment for aortic root pathology in 
Marfan syndrome, namely, Pravastatin.
11
General Introduction
1.1 Introduction:
Marfan syndrome is an autosomal dominant inherited disorder due to a defective form of 
the fibrillin-1 gene. Aortic pathology presents the major challenge and is responsible for 
the most significant morbidity and mortality, through the complications of aortic 
aneurysm, dissection, and aortic regurgitation. Through the development of the Marfan 
murine models, we now understand that aortic pathology in Marfan syndrome is not due 
to a congenital defect in elastogenesis but rather to secondary haemodynamic and 
inflammatory processes that develop as a consequence of lack of fibrillin-1 expression 
(Ramirez and Pereira 1999; Bunton, Biery et al 2001). This suggests that 
pharmacological therapy to modify these processes may be useful in ameliorating aortic 
pathology, particularly if they are applied in a prophylactic form before clinically 
detectable aortic pathology develops.
Statins (HMG-CoA reductase inhibitors) are commonly used, relatively safe drugs, 
developed for the management of hypercholesterolaemia. They represent a drug that 
patients are generally started on for lifelong therapy. Used in the management of 
documented vascular disease they have also been shown to have anti-inflammatory 
actions through inhibition of certain MMP (matrix metalloproteinases) secretion from 
monocytes(Grip, Janciauskiene et al. 2002), macrophages(Bellosta, Via et al 1998; 
Luan, Chase et al. 2003) and vascular smooth muscle cells(Luan, Chase et a l 2003); as 
well as anti-proliferative and anti-migratory effects on vascular smooth muscle 
cells(Porter, Naik et al. 2002). It is these properties of statins combined with their
Chapter 1
12
prophylactic use before aortic inflammation and elastolysis develops that could be 
particularly beneficial in Marfan syndrome.
Figure l.l{Ref.:www.marfanresearchfoundation.ie (with permission from author 
given by Dr.John Byrne)}: The diagram above and to the left, shows a normal heart 
with the arrow pointing to the beginning of the aorta as it leaves the heart called the 
"aortic root”. The middle diagram shows the heart of a person with Marfan 
syndrome showing dilation of the aortic root which predisposes to a leaky aortic 
valve, excessive enlargement where the aorta can rupture called an aneurysm, or 
spontaneous tearing of the wall of the aorta called a dissection. The diagram on the 
right shows the heart of a patient with Marfan syndrome who has had surgery to 
replace the aortic root and valve with an artificial tube and mechanical valve to 
prevent development of an aneurysm or dissection, or to repair a leaking stretched 
aortic valve.
1.2 Background:
Marfan syndrome is uncommon, but cardiovascular pathology occurs in more than 90% 
of those affected and manifests in young people often necessitating complex cardiac and
13
aortic surgery. In many cases, surgery arises as an emergency due to aortic dissection or 
symptomatic aneurysm, but with increasing awareness among both physicians and the 
population in general, there is now a move towards earlier surgical intervention when 
aortic root size is increasing on serial echocardiography, computed tomography or 
magnetic resonance angiography studies. Of note, echocardiographic studies measure the 
internal diameter, whereas most patients undergo definitive imaging by CT and/or MR, 
which measures the external diameter (expected to be 0.2 to 0.4 cm larger than internal 
diameter), and external diameter is the measurement used in most cases to determine the 
threshold for surgical repair. Aortic root replacement then removes the potential risk of 
Type A dissection, ascending aortic aneurysm formation and aortic regurgitation There 
are a number of classification systems to stage dissection of the aorta. The Stanford 
classification of aortic dissection distinguishes between type A and type B. (DeBakey, 
Beall et al. 1966) Type A means the dissection involves the ascending aorta, whereas type 
B dissection does not involve the ascending aorta. The De Bakey classification 
subdivides the dissection process, with type I  dissection involving the entire aorta, type II 
dissection involving only the ascending aorta, and type III dissection sparing the 
ascending aorta and the arch.(Debakey, Henly et al. 1965) Various attempts to further 
subdivide both classifications have not yet been established in the medical 
community.(Lansman, McCullough et a l 1999) There is also an established benefit with 
the use of beta blockers to retard aortic dilation in those with documented aortic 
enlargement. However, there is currently no treatment to delay or attenuate the 
development of aortic pathology.
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Figure 1.2: Transthoracic echocardiogram of a patient with Marfan syndrome with 
mitral valve (green arrow) prolapse and 4-cm ascending aortic aneurysm (white 
arrow).
Figure 1.3: Axial CT images of an aortic root aneurysm, non-contrast (left) and 
contrast (right). White arrows display the aortic wall and black arrow displays the 
dilated aortic root diameter.
In a study of life expectancy of patients with Marfan syndrome published in 1995, 
cardiovascular complications which were the cause of death in patients were as follows: 
congestive heart failure, aortic dissection, aneurysm rupture, sudden death, perioperative
15
and others(including cerebral haemorrhage, myocardial infarction, arrhythmia and 
infective endocarditis).(Silverman, Burton et al 1995) The mean age of death in this 
study was 41+/-18 years compared to 32+/-16 years in 1972.(Murdoch, Walker et al 
1972) Life expectancy continues to improve with improved diagnosis, prospective 
management, lifestyle adaptations, beta-blockade and most importantly aortic aneurysm 
repair.(Pyeritz 2009) Despite these measures, causes of late death in patients after aortic 
aneurysm repair include: rupture/dissection of an aneurysm, congestive heart failure, 
perioperative death during subsequent aneurysm surgery, stroke, arrhythmia, prosthetic 
valve endocarditis, and valve failure.(Finkbohner, Johnston et a!. 1995)
Much of our new understanding of aortic pathology in Marfan syndrome comes from the 
development of the Marfan mouse (Pereira, Andrikopoulos et al 1997). The discovery 
that the problematic gene in Marfan syndrome was fibrillin 1, a component of 
microfibrils, allowed for the development of two forms of the Marfan mouse(Arteaga-
Solis, Gayraud et al. 2000). The mgA mouse has internally deleted fibrillin-1 proteins at a
level that is 10 times less than that expressed normally and is a structurally smaller 
protein. The homozygous mg* mouse dies within 2 weeks of birth from aortic
complications which limits the ability to follow the natural history of the disease 
(Arteaga-Solis, Gayraud et al. 2000). However, the homozygous mgR mouse possesses 4 
times less fibrillin-1 protein than normal and the protein is of the same size as the wild 
type fibrillin-1 protein. This produces a mouse that dies of aortic complications between 
12 and 24 weeks of age, allowing for more detailed study of the natural history of aortic 
pathology (Arteaga-Solis, Gayraud et al 2000). Examination of pathological vascular
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specimens from patients who died with Marfan syndrome or who underwent aortic 
surgery shows that the changes that occur in the elastic vessels of these patients are the 
same that one sees with the mgR mouse, again reinforcing the suitability of this model for 
interventional studies (Bunton, Biery et al 2001). The problem with the mgR mouse is 
that they are homozygous recessive which does not mirror the true clinical scenario in 
which patients with Marfan syndrome inherit it in an autosomal dominant manner.
Figure 1.4: X-ray images of the C1039G “Marfan-mouse” on left (with prominent 
thoracic kyphosis) and wild-type mouse on right.(Judge, Biery et a l 2004)
Recently a team at Johns Hopkins University successfully developed a heterozygous 
Marfan mouse that has a missense mutation in the fibrillin-1 gene sufficient to cause the 
phenotypic problems with Marfan syndrome when only one copy of the mutated fibrillin- 
1 gene is inherited. This allows for an autosomal dominant pattern of inheritance similar 
to the clinical situation. These mice have the mutation C1039G in which a cysteine 
residue in the fibrillin-1 protein is replaced with glycine, and mirrors a mutation seen in 
patients with Marfan syndrome. The heterozygous C1039G Marfan mouse has a reduced 
amount of microfibrils as a result of the mutation which produces skeletal deformities 
and deterioration in aortic wall architecture, similar to the changes seen in human Marfan 
syndrome. These Marfan mice however, do not die of aortic dilation related
17
complications but do develop aortic wall thickening and classic Marfan-type histological 
changes within the aortic wall (Judge, Biery et al. 2004).
Vascular smooth 
muscle cell
] Microfibrils
1 Elastin
Figure 1.5: Diagram of arrangement of vascular smooth muscle cell, elastin and 
microfibril assembly (polymerised fibrillin-1)
In order to understand the aortic pathology in Marfan syndrome, knowledge of normal 
aortic structure and function is essential. Common to all vessels is an intima composed of 
an endothelial monolayer, and an adventitia composed of fibrous collagen bundles. It is 
the intervening medial layer that varies depending on vessel size and function. The aortic 
medial layer is composed primarily of elastic fibres, with some smooth muscle cells, 
unlike smaller vessels which would have a more muscular medial layer(Ramirez and 
Pereira 1999). The function of this is that the elastic medial layer provides a very 
compliant vessel that can resist dynamic systolic and diastolic pulsations, transmitting a 
pulse wave along the arterial tree(Ramirez and Pereira 1999). The elastic aortic medial 
layer is composed of elastin fibres interwoven in a matrix of microfibrils (Arteaga-Solis, 
Gayraud et al. 2000). The fibrillin-1 protein that is defective or diminished in Marfan
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syndrome is a protein component of microfibrils. Microfibrils through fibrillin-1 provide 
anchoring connections to surrounding smooth muscle cells, the endothelial monolayer, 
and connective tissue of the adventitia (Ramirez and Pereira 1999; Arteaga-Solis, 
Gayraud et al. 2000). Microfibrils have been described as, "flexible links that make the 
aortic wall a working unitM(Arteaga-Solis, Gayraud et al. 2000):
1.3 Pathogenesis of aortic disease in Marfan syndrome.
Initially it was thought that fibrillin-1 deficiency leads to impaired elastic fibre formation 
in the embryo producing a congenitally weak aortic wall.(Ramirez and Pereira 1999) We 
now realize that this is not the case and that fibrillin-1 appears to play a role in the normal 
homeostasis of the aortic wall.(Ramirez and Pereira 1999; Bunton, Biery et al. 2001) The 
pathological consequences of a fibrillin-1 deficiency are not purely due to the mechanical 
stress being imposed on an intrinsically weak, poorly connected medial aortic layer. 
Vascular smooth muscle cells which have lost their fibrillin-1 connectivity appear to 
acquire abnormal synthetic and inflammatory properties (Bunton, Biery et al. 2001). This 
is often an early detectable change in the aortic wall, where the smooth muscle cells 
secrete more matrix components and MMP-9, one of the main metalloproteinases 
mediating elastic fibre destruction (Bunton, Biery et al. 2001). This leads to the initial 
phase of elastic fibre fragmentation (Bunton, Biery et al. 2001). Macrophages then seem 
to localize to these sites of elastic fibre damage and liberate more metalloproteinases in a 
second more intense inflammatory phase.(Pereira, Lee et al. 1999; Bunton, Biery et al. 
2001) When this is coupled with intense haemodynamic strain, and the loss of tensile 
strength from lack of fibrillin connections with the collagenous adventitial layer, aortic
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dilation ensues.(Pereira, Lee et a l 1999; Ramirez and Pereira 1999; Arteaga-Solis, 
Gayraud et a l 2000) In advanced stages there is an intense infiltration of macrophages at 
the adventitial surface of the elastic medial layer, which extend into a now severely 
diminished aortic medial layer, predisposing to pathological aneurysmal dilation and 
dissection (Pereira, Lee etal. 1999).
It is this inflammation mediated matrix destruction both early with vascular smooth 
muscle cell induced matrix destruction through MMP-9, and later with macrophage 
induced elastolysis, that may be able to intervene against clinically(Arteaga-Solis, 
Gayraud et al. 2000; Bunton, Biery et al 2001). The ability to provide an anti­
inflammatory strategy prophylactically in this scenario to minimize secondary events 
may maximize any potential therapeutic benefit.
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Figure 1.6: Diagrammatic representation of the vascular smooth muscle cell (yellow) 
and pathophysiology involved in Marfan syndrome. Fibrillin-1, is an important 
component of the elastin (brown) microfibril. It is secreted as a proteoglycan into 
the extracellular matrix and polymerises to form microfibrils. These microfibrils 
help to stabilise a complex that includes latent transforming growth factor-beta and 
transforming growth factor-beta. With less fibrillin-1, there is less latent 
transforming growth factor-beta to bind with transforming growth factor-beta, and 
thus it becomes active transforming growth factor-beta (blue & yellow star). It then 
activates the Smad cascade (green) by interacting at the cell membrane receptor 
(white). The Smad cascade induces transcription at the level of the nucleus (purple). 
Excess messengerRNA for matrix metalloproteinases (orange) and proteoglycan 
(pink), such as Versican are transcribed. These are then processed by the rough 
Endoplasmic Reticulum and secreted by the Golgi complexes.
1.4 Beta-blockade therapy
Propranolol is a non-selective beta-blocker which is mainly used in the treatment of 
hypertension. Its use has been advocated as a preventative therapeutic strategy to 
decrease the rate of aortic root dilatation and progression to aortic root dissection in 
patients with Marfan syndrome. Beta-blockade is used conceptually because of the 
negative inotropic and chronotropic effects on the heart. The proposed mechanisms of 
benefit of beta-blockers in Marfan syndrome include reduction in the rate of pressure 
increase in aorta (dP/d/) and reduction in heart rate, which reduces the number of systolic
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impulses in a given period.(Prokop, Palmer et al 1970) However, several studies have 
shown that beta-blocker treatment may not produce the desired haemodynamic effects in 
patients with marked dilation of the aortic root. (Yin, Brin et a l 1989; Baumgartner, 
Baumgartner et a l 2006) Atenolol, a selective (31 inhibitor which more effectively 
reduces contractility and slows the heart rate, would in theory be more suitable for this 
purpose, with a lower side-effect profile. Some studies have shown slower aortic root 
growth, fewer cardiovascular end points (defined as aortic regurgitation, dissection, 
surgery, heart failure or death), and improved survival.(Shores, Berger et al. 1994) The 
response to beta-blocker therapy has been found to be heterogeneous.(Rios, Silber et al
1999) Responders tended to be younger, with a smaller more compliant pre-treatment 
aorta. Non-responders tended to have more elastic fibre degeneration and more advanced 
disease of the aorta. A recent meta-analysis concluded that there is no evidence that beta- 
blockade therapy has a clinical benefit in patients with Marfan syndrome. (Gersony, 
McCIaughlin et al 2007)
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Figure 1.7: Diagram of normal and dilated aortic root with origin of coronary 
arteries and proximal branches of the aorta. Arrow showing direction of transmural 
pressure at which the change in pressure (dP/dt) affects the aortic wall. Original 
diagram from British Medical Bulletin(De Mozzi, Longo et al. 2008)
1.5 Surgical treatment
If medical treatment fails, and aortic root dilatation reaches 5cm or more, prophylactic 
surgery should be considered.(Groenink, Lohuis et al. 1999) One can also refer to a Z- 
score, which compares the maximum dimension at the level of the sinuses of Valsalva 
and compares to the predicted dimension for that person’s body surface area.(Colan, 
McElhinney et al. 2006) Other factors such as sex, (one study suggests a threshold 0.5cm 
lower in females(Meijboom, Timmermans et al. 2005)), family history of dissection and 
aortic root growth rate of more than 0.5cm per year.(Hiratzka, Bakris et al. 2010) The
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options for surgical repair include the Bentall composite graft repair, in which both the 
aortic root and the aortic valve are replaced, or a valve conserving technique such as re­
implantation of the native aortic valve in a Dacron tube (described by David et al. 2003) 
or remodelling of the aortic root (de Oliveira, David et a i 2003; Nataf and Lansac 2006) 
The Bentall procedure has a low mortality in experienced hands with a favourable long­
term survival, though long term anti-coagulation is required for mechanical valves. 
Aortic valve re-implantation techniques have also shown durability of the aortic valve. 
(Kallenbach, Karck et a i  2005)
Figure 1.8: Drawing of implanted conduit with coronary arteries anastomosed to 
composite graft. Photograph of composite conduit with mechanical valve and 
Dacron tubing.(Lansac 2007)
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The concept of therapeutic intervention for the aortic pathology of Marfan syndrome 
stems from the fact that the inflammatory fibro-proliferative response of macrophages 
could be attenuated with anti-inflammatory agents (Arteaga-Solis, Gayraud et al. 2000). 
Macrophages localize to the sites of elastic fibre fragmentation, and play a clear role in 
elastolysis (Arteaga-Solis, Gayraud et al. 2000). However, this occurs at a much later 
stage when significant elastic fibre destruction has already occurred. An even better 
strategy would be to intervene to prevent this occurring, i.e. at the stage in which vascular 
smooth cells are producing excessive matrix elements and secreting MMP-9 locally 
causing the initial phase of elastolysis (Bunton, Biery et al. 2001). This earlier process 
eventually leads to breach of the internal and external elastic laminae which then allows 
infiltration of inflammatory cells such as macrophages into the medial layer to cause the 
later intense elastolysis (Bunton, Biery et al. 2001). The importance of early MMP-9 
production by the vascular smooth muscle cells is evidenced by the fact that 
immunoreactivity for MMP-9 is seen in early lesions before overt elastolysis or 
infiltration of inflammatory cells into the media (Bunton, Biery et al. 2001). Additionally, 
local expression of MMP-9 in the aortic media correlates with the extent of loss of elastin 
content, and elastic fibre architecture (Bunton, Biery et al. 2001). It has even been 
suggested that these enzymes from smooth muscle cells, such as MMP-9 may be 
sufficient to promote aneurysmal formation in patients with Marfan syndrome as the 
elastin that exists may be more prone to MMP-9 destruction due to a lack of fibrillin- 
1 (Marque, Kieffer et al. 2001). This early enhanced MMP-9 expression is not limited to
1.6 New potential therapeutic intervention
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aortic pathology, but has also been described in the lungs of the Marfan mouse (Neptune, 
Frischmeyer et al. 2003).
As a result current interest exists in the antibiotic drug Doxycycline, which is a non- 
specific inhibitor of matrix metalloproteinases (Boyle, McDermott et al. 1998; Lalu, Gao 
et al. 2003; Peterson 2004). Doxycycline has mainly been investigated in relation to 
abdominal aortic aneurysm disease. In a rodent model of elastase induced aneurysms, 
pre-treatment with Doxycycline effectively suppresses the development of aneurysms 
and is associated with reduced aortic MMP-9 levels combined with reduced elastin 
destruction(Boyle, McDermott et al. 1998). In patients with established atheromatous 
abdominal aortic aneurysms, treatment with oral Doxycycline for 7 days prior to 
aneurysm repair significantly reduces aortic MMP-9 mRNA levels (Curci, Mao et al.
2000). Studies are currently underway using the Marfan mouse looking at the potential 
therapeutic benefit of Doxycycline treatment.
1.7 Losartan
Losartan belongs to the angiotensin II receptor antagonist class of drugs. Recent studies 
in a mouse model of Marfan syndrome with aortic disease similar to that seen in humans 
compared treatment with Losartan to propranolol. Losartan treatment prevented elastic 
fibre fragmentation, blunted TGF-beta signalling in the aortic media and normalized 
aortic root growth in comparison to propranolol and control groups.(Habashi, Judge et al. 
2006) Elevated levels of Transforming Growth Factor Beta (TGF-P) activate the TGF-p 
receptor at the level of the cell membrane, which signals the receptor complex to 
phosphorylate Smad-2, which activates the Smad cascade within the cell, in turn
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activating release of excessive amounts of matrix metalloproteinases. Losartan has been 
found to down-regulate the expression of TGF-p receptors Type I and II in a model of 
diabetic nephropathy in rats.(Guo and Qiu 2003) Losartan has an effect of reducing the 
level of TGF-p signalling and so the levels of phosphorylated Smad2 are 
reduced. (Habashi, Judge et al. 2006) This in turn, has reduced the destructive effect of 
excessive TGF-p levels on the cell matrix.
There is also a clinical trial using Losartan in Marfan syndrome patients tinder the age of 
25 years which is in progress. (Lacro, Dietz etal. 2007; Brooke, Habashi et al 2008)
1.8 Statins inhibit MMP-9 production
Statins were initially developed to manage hypercholesterolaemia by reducing 
endogenous hepatic cholesterol production through inhibition of the enzyme HMG-CoA 
reductase. In clinical practice, it was noted that patients on statins had less acute 
cardiovascular events before any angiographic improvements in their coronary disease 
were detectable with imaging studies(Crisby, Nordin-Fredriksson et al 2001). This 
suggested that the statins were also working to stabilize the atherosclerotic plaques. This 
plaque stabilization was not just due to a reduction in lipid content of the plaque, but also 
due to reduced inflammation within the plaque (Crisby, Nordin-Fredriksson et a l 2001). 
When carotid plaques removed at endarterectomy from patients on statins are compared 
to those not on statins, they are shown to contain fewer macrophages, fewer T cells, less 
MMP-2 activity, reduced vascular smooth muscle cell apoptosis, enhanced TIMP-
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¡(tissue inhibitor of metalloproteinases-1) activity, and increased collagen levels(Crisby, 
Nordin-Fredriksson el a l 2001). Similarly, patients with acute coronary syndromes have 
elevated serum MMP-2 and MMP-9 levels which decrease significantly with 30 days of 
treatment with statins (Tziakas, Chalikias et a l  2004). Statins have been shown to 
attenuate MMP production from a number of cell types including human vascular smooth 
muscle cells isolated from peripheral veins(Luan, Chase et al. 2003), aortic vascular 
smooth muscle cells (of particular interest in Marfan syndrome)(Luan, Chase et al. 2003), 
macrophages (also of interest in those with Marfan syndrome)(Bellosta, Via et a l 1998), 
monocytes, and even in the aneurysmal wall removed from patients with abdominal 
aortic aneurysms subsequently cultured in-vitro(Nagashima, Aoka et al. 2002). In the 
case of human vascular smooth muscle cells treated with statin doses used clinically as 
"high dose" statin, there is significant inhibition of inducible MMP secretion, i.e.: MMP- 
1 secretion reduced by 52%, MMP-3 secretion reduced by 71%, and MMP-9 secretion 
reduced by 73% (P<0.01)(Luan, Chase et al. 2003). One of the key potential benefits for 
Marfan syndrome is that statins appear to inhibit MMP secretion from vascular smooth 
muscle cells no matter what the stimulus is for that MMP secretion (Bellosta, Via et al. 
1998; Luan, Chase et a l 2003). This is because this process is not lipoprotein dependent, 
but instead involves post-transcriptional inhibition (Crisby, Nordin-Fredriksson et al. 
2001; Luan, Chase et al. 2003). Fortunately, this post-transcriptional inhibitory 
mechanism of statins is selective for MMP’s and not merely an overall inhibitory effect 
on protein synthesis (Luan, Chase et al. 2003). Additionally, a reduction in serum MMP- 
9 activity occurs not only in individuals with hypercholesterolaemia but also in healthy 
people on statins which suggests that those with Marfan syndrome may also be able to
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benefit from a reduction in MMP-9 levels with statin use(Tziakas, Chalikias et a l  2004). 
Statins also do not affect production of TIMP-1 or TIMP-2 (endogenous inhibitors of 
MMP activity), which further shifts the MMP / TIMP balance towards inactive enzymes 
(Luan, Chase et a l 2003).
Statins have also been shown to attenuate intimal hyperplasia through reducing vascular 
smooth muscle cell proliferation and migration (Porter, Naik et a l  2002). Statins have 
been shown to inhibit the proliferation, migration and invasion of vascular smooth 
muscle cells from saphenous veins. This appeared to be due to inhibition of 
prenylation. (Porter and Turner 2002)They also are anti-inflammatory through inhibition 
of NFkP and AP-1, important transcription factors in inflammation (Dichtl, Dulak et a l
2003). Both of these effects could be of benefit in the aortic pathology with Marfan 
syndrome.
The intracellular mechanism of action of statins is illustrated below:
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Figure 1.10: The HMG Co-A pathway with diagrammatic representation of the 
effect of statin therapy on this pathway.
Isoprenoids have important roles in mammalian cells in prénylation of proteins, a process 
which is required for their membrane localization and function(Zhang and Casey 1996). 
Statins are potent inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
and thereby affect the mevalonate pathway, which is important for the biosynthesis of 
isoprenoids such as geranylgeranyl pyrophosphate (GGPP) and farnesyl pyrophosphate 
(FPP), as well as cholesterol.(Goldstein and Brown 1990) GGPP and FPP are important 
lipid attachments for the posttranslational modification of several proteins that include 
the small GTP-binding proteins Ras, Rac, and Rho. Attachment of these lipids, so-called 
isoprenylation, is essential for activation and intracellular transport of proteins crucial for
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various cellular functions, such as maintenance of cell shape, motility, factor secretion, 
differentiation, and proliferation. A decrease in HMG-CoA results in a decrease in the 
components of the pathway which finally results in less intracellular transport and less 
cistemae/Golgi.
It seems that statins have an effect on lipid raft-mediated intracellular transport and cell- 
surface expression of a variety of molecules or on the activation of certain proteins by 
isoprenylation, thereby affecting many cellular functions. Experimentally inhibiting such 
prenylation of a protein called Rab leads to a block in protein secretion from the 
cell(Bellosta, Via ei al. 1998). This could have benefits in limiting excessive secretion of 
matrix elements from vascular smooth muscle cells in those with Marfan syndrome. In 
fact, it has been previously noted that the selected vascular smooth muscle cell and 
connective tissue abnormalities seen in Marfan syndrome are also common in the 
maturation of atheromatous lesions (Bunton, Biery et al. 2001). It is this exact pathology 
that statins appear to intervene in producing their "plaque stabilizing" effect. Clearly 
these parallels suggest a benefit for statin use in Marfan syndrome.
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The natural history of Marfan syndrome will be investigated. Investigation will include 
in-vivo physiological measurement of the aortic root diameter, with a view to 
documenting progression of pathological dilatation and to compare these measurements 
to observed measurements of normal growth in a wild-type murine model. A histological 
analysis will be conducted to compare observed changes in the size of the aneurysm in- 
vivo and the pathological histology changes observed. The ultra-structure of the cells 
within the aortic wall tissue will be examined and analysed, with enumeration of the cell 
organelles or estimation of the volume of the cell organelles. The application of statins in 
a prophylactic setting for lifelong use will be investigated in terms of potential to 
attenuate the development and course of aortic pathology associated with Marfan 
syndrome. Statin therapy will be compared to angiotensin II receptor antagonism and 
Doxycycline therapy, using both physiological and histological parameters.
1.9 Aims of thesis
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Chapter 2
Materials & Methods
2.1 A study of aortic root pathology in a murine model of Marfan syndrome.
2.1.1 Background
Mice heterozygous for a missense mutation in the fibrillin-1 gene which leads to a 
cysteine substitution in a calcium binding epidermal growth factor like domain of the 
fibrillin-1 protein (C1039G) express the phenotypic features of human Marfan syndrome. 
In particular they develop skeletal abnormalities, and progressive aortic pathology and 
dilatation. These mice transmit the mutation in an autosomal dominant fashion.
2.1.2 Genetically typing the C1039G murine model
A number of C1039G Marfan mice were cross bred with C57B16 females. C1039G mice 
were gifted from Department of Genetics and Cardiology, Johns Hopkins University. 
Marfan syndrome is inherited as an autosomal dominant disorder with high penetrance, 
but has great clinical variety in humans.(Dietz, Cutting et a i  1991) A high proportion of 
patients with Marfan syndrome manifest aortic pathology with an aortic root aneurysm. 
Once C1039G mice were identified for our study and entered into control groups, 
measurements of aortic root parameters were made at defined time-points to assess 
phenotypic expression of aortic root pathology as outlined in sections 2.1.4, 2.1.5, 2.1.6 
& 2.1.7. Following weaning, male mice were identified and a small tail tissue sample 
was obtained from the offspring under Isoflurane anaesthesia (1-2% Forane, Abbott, 
Ireland). A small identifying tag was placed on the right ear to identify them for the 
duration of the study. DNA was isolated using a DNA extraction kit (DNA purification
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kit, Al 125, Promega, USA). The protocol used at Johns Hopkins University was used 
here to identify the mice. PCR was performed to amplify a 600bp fragment of the 
fibrillin-1 gene containing the missense mutation. The primers used for PCR were intron 
24s (TTGTCCATGTGCTTTAAGTAGC) and intron 25s
(ACAGAGGTCAGGAGATATGC) (Genosys, Sigma, UK). Successful PCR of the 
600bp fibrillin-1 gene fragment was confirmed by gel electrophoresis.
Figure 2.1 Electrophoresis bath, suitable for gel electrophoresis, with connection to 
power supply.
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An 11% agarose gel was used as media for gel electrophoresis run at 9V/cm current for 
40 minutes. The gel is impregnated with Ethidium Bromide and so DNA fluoresces under 
ultraviolet light. The positive bands show up bright in relation to a base pair ladder which 
is also loaded onto the gel. C1039G Marfan mice were identified by the presence of a 
Kpnl restriction site introduced by the mutation into the fibrillin-1 gene. This was 
achieved using the restriction enzyme Asp 718 (Roche, UK) which split the PCR product 
containing the missense mutation into a 350bp and 250bp fragment(Judge, Biery et al
2004) (Figure 2.2).
Figure 2.2: Gel electrophoresis, impregnated with Ethidium Bromide, illuminated 
with ultraviolet light, showing a base-pair ladder on the left and two “lanes” the 
first showing a 600bp fragment (homozygous for fibrillin-1) and the second showing 
a 350 & 250bp fragment (heterozygous for fibrillin-1).
The substrate was then subject to agarose gel electrophoresis. The gel was then analysed 
and imaged under ultraviolet light. Male mice were assigned as either wild type or
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heterozygous Marfan mouse and the heterozygous Marfan mice were assigned to 
different groups according to each experimental protocol. Wild type mice that were 
entered into this study were bred from C57black6 with both male and female being wild 
type, free of genetic mutation. In the initial development of the C1039G model, 
homozygous Marfan mice developed a severe form of the disease and died 
perinatally.(Judge, Biery et al 2004) Heterozygous Marfan mice showed kyphosis of the 
thoracic spine, so penetrance of the C1039G mutation could be confirmed 
phenotypically. In the untreated Marfan groups, the diameter of the aortic root showed 
the presence of aneurysmal dilatation which showed that those which were positive on 
testing genetically also had more than one phenotypic change.
Untreated C1039G Marfan mice were compared to normal C57black 6 mice as controls. 
The natural history of the disease compared to normal growth was examined. The aortic 
root diameter, cardiac function and aortic pathology at different time-points of 
development was observed.
2.1.3 Drug administration
For the comparison study of different pharmaceutical therapies, Pravastatin (Bristol 
Myers Squibb, USA), Losartan potassium (Sigma, Europe), or Doxycycline (Sigma, 
Europe) was administered from a 6 weeks of age, in the drinking water using a 
gravimetric dosing system. Equal volumes of water per mouse (or water with relevant 
drug added as per protocol concentration) was added to the gravimetric dosing system on 
a weekly basis. The volume remaining in the gravimetric dosing system prior to refilling 
was measured to assess the volume consumed by each litter of mice from the previous
39
week to ensure adequate dosing. Note was also made of the hydration status of each 
mouse to ensure adequate and equal intake of fluid. The concentrations of each drug used 
for each treatment regimen, along with that of the control groups, is specified in sections 
3.2, 4.3 and 5.2 of chapters 3, 4 and 5, respectively for each of the three different 
experimental protocols.
2.1.4 Transthoracic echocardiographic measurements of aortic root diameter
Mice underwent 2 Echo measurements of their aortic root diameter at 3 and 8 months of 
age: Measurements were made, in association with the Department of Veterinary 
Medicine in University College Dublin, by members of the veterinary radiology team 
(University College Dublin). Transthoracic ECHO (Acuson Sequoia, Siemens) was used 
with a 12 MHz probe which the veterinary radiology team has successfully used 
previously to image the hearts of COX-2 knockout mice.(Neilan, Doherty et al 2006) 
These mice were of the same size as Marfan mice and clear aortic root images were 
obtainable. Echocardiography is considered a reliable and validated method to measure 
aortic root dimensions of murine models in-vivo.(Liu and Rigel 2009)
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Measurements of aortic root diameter were made in the parasternal long axis view at 
sinus level, from leading edge to leading edge (Figure 2.3). An average of three 
measurements for each mouse was taken at each sitting, by two experienced 
sonographers blinded to the genotype and treatment group. Images were stored as TIFF / 
JPEG files. With the assistance of a specialist small animal veterinary anaesthetist, for the 
purpose of conducting echocardiography, each mouse was anaesthetized with Isoflurane 
in an anaesthetising box and maintained under anaesthesia using Isoflurane via a face- 
cone with 100% 02. After the ECHO, the mice were recovered under a heat lamp in their 
cage and observed until fully mobile again.
2.1.5 Millar cardiac catheter measurements of aortic and ventricular pressures
Within 2 weeks of the final 8 month echocardiogram being completed, the mice were 
anaesthetized for cardiac catheter measurements. Following anaesthesia with intra- 
peritoneal xylazine lOmg/kg (Xylapan, Vetoquinol, France) and ketamine lOOmg/kg
Figure 2.3: Parasternal long axis view of aortic root.
(Kctalar, Pfizer, Ireland), a midline vertical neck incision was made and the right carotid 
artery was exposed. Proximal and distal control of one carotid was obtained with 6/0 
suture material Using an operating microscope, a 1.2 French Millar cardiac catheter was 
introduced into the carotid artery with minimal blood loss. Once an aortic pressure trace 
was obtained the animal had a period of stabilization. A recording was then taken of the 
aortic pressure wave and a reading of systolic and diastolic blood pressure taken. The 
aortic pressure trace was shown to a cardiologist blinded to the treatment groups and 
asked to comment as to whether they thought it exhibited features consistent with aortic 
regurgitation. The dP/dt max of the aortic downstroke was analysed, a positive value 
confirms that an upstroke was present. This upstroke reflected the presence of an aortic 
dicrotic notch and a negative value showed that the dicrotic notch was absent. The 
catheter was then advanced into the left ventricle and again followed by a period of 
stabilization. A 30 second recording of left ventricular pressure changes was taken. 
Powerquest software was used to analyse the pressure tracings. These recordings were 
used to calculate dP/dt max, dP/dt min, left ventricular end diastolic and end systolic 
pressure. Three readings from the 30 second transducer trace recording were then 
averaged. The left ventricle contractility index (dP/dtmax divided by LVEDP; p=pressure, 
t=time, LVEDP left ventricular end diastolic pressure) was used as a measure of cardiac 
function and hence haemodynamic stress on the aorta. Dr. Gang Chen contributed to this 
section of the experiments by facilitating measurement of both aortic pressure tracing and 
left ventricular pressure tracings. He conducted the micro-vascular technique of isolation 
of the right carotid artery, subsequent insertion of the Miller cardiac catheter into the 
aorta and advancement of the catheter into the left ventricle.
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At the end of the cardiac catheterization, the catheter was carefully removed. The mice 
were euthanized with an overdose of intra-cardiac sodium pentobarbital. The mice then 
underwent cardiac puncture, obtaining a 0.8ml blood sample, which was saved for further 
studies. The heart and aorta (to the level of the diaphragm) were excised en bloc and 
fixed in 10% buffered formalin for 24 hours followed by processing for paraffin 
embedding. 5 micrometer sections of the aortic root were cut to achieve circular cross 
sections.The lungs were also excised individually. Tissues were fixed in 10% buffered 
formalin overnight, processed for paraffin embedment and sectioned at 5 micrometers. 
These slides were then stained with haematoxylin and eosin. Sectioning and staining 
were performed by the Department of Pathology, RCSI.
Haematoxylin and eosin stains were used for stereology. Images were photographed 
(Nikon Coolscope, Nikon) and image analysis software (Image Pro Express, Media 
Cybernetics) used to measure the thickness of the medial layer of the aortic root.
2.1.6 Harvesting tissues & histological analysis
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Figure 2.4 A - D. A, image of aortic cross-section loaded into Image-Pro Express® 
for analysis. B, inner aspect of aortic medial wall plotted, with more than 40 points 
identified with “image wizard” assistance. C, outer aspect of aortic medial wall 
plotted, with more than 40 points identified, again with “image wizard” assistance. 
D, with both aspects of aortic medial wall identified, the software calculates the 
average distance between the two line, which relates to the average thickness of the 
aortic medial layer.
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The V-VG stain for elastic tissue content of the aortic root was used to assess the degree 
of fragmentation of the elastic fibres. A modification of a previously published 
technique was used to quantify aortic pathology (Habashi, Judge et al. 2006) . Two 
independent observers blinded to the genotype and treatment group scored each slide 
using an arbitrary scoring system which counted the number of “islands of damage” 
within an aortic cross-section from each mouse. An “island of damage” was defined as an 
isolated area of aortic wall where 2 adjacent elastic fibres were fragmented with 
interposed excessive connective tissue matrix.
Figure 2.5: Light microscopy image: Verhoeff-Van Gieson stained cross-section of 
aortic root of a wild-type mouse at 8 months, magnification xlO. Normal aortic wall 
is displayed (yellow arrows) with the usual arrangement of elastin (red circle).
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Figure 2.6: Light microscopy image: Verhoeff-Van Gieson stained cross-section of 
aortic root of a “Marfan” mouse at 8 months, magnification x20, displaying an 
island of damage (yellow circle). The aortic wall is thickened with loss of the usual 
arrangement of elastin.
Aortic root sections were also stained with Alcian blue stain for collagen content.
2.1.7 Electron Microscopy protocol
Examination of the aortic tissue specimens with electron microscopy was conducted in 
collaboration with the Department of Anatomy in the National University of Ireland in 
Galway. The aortic root was dissected out and immersion fixed in primary fixative, 2% 
Glutaraldehyde + 2% Paraformaldehyde in 0.1M Sodium Cacodylate/ HC1 buffer 
pH7.2.They were stored in the primary fixative until delivery to the Anatomy Department, 
NUI Galway. Members of the Department of Anatomy of NUI Galway conducted the 
secondary fixation and processing of the aortic tissue samples, followed by imaging at an 
ultra-structural level and subsequent stereological quantification of the cell organelles.
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Samples were rinsed in freshly prepared 0.2M Sodium Cacodylate/HCl Buffer pH7.2 (3 *10 
mins). Samples were then immersion fixed in secondary fixative, 1% Osmium Tetroxide in 
0.1M Sodium Cacodylate/ HC1 buffer pH7.2 (2 hrs). Following fixation, samples were 
dehydrated through a series of graded alcohols (40%, 50%, 70%, 80%, 90%, 95% and 100%) 
and routinely embedded in an Agar Low Viscosity Resin.
Histological Protocol:
Light microscopy images were taken to confirm aortic root samples without the presence of 
artefact. Semi-thin sections (0.75 ^m thick) were cut using a glass knife and a Reichert-Jung 
Ultracut ultramicrotome, (Boeckeler Instruments, Inc., Arizona, U.S.). The sections were 
placed on glass slides and stained for 8 seconds with toluidine blue. Sections were examined 
on a Leica Bright Field Microscope Serial# 14003 connected to a computer with Leica 
Application Suite microscope software, (Leica Microsystems Inc., Bannockburn, U.S.). 
Several images were taken of each tissue sample at *10 and x 40 objective magnifications, 
two were chosen from each sample on which to carry out stereological analysis. For TEM, 
ultra-thin sections (0.5 jim) were cut using a diamond knife and a Reichert-Jung UltracutE 
ultramicrotome. The sections were placed on 200 |im mesh copper grids and stained with 
uranyl acetate and lead citrate using a Leica EM AC20 Autocontraster, (Leica Microsystems 
Inc., Bannockburn, U.S.). Sections were examined on a Hitachi H7000 Transmission 
Electron Microscope, (Hitachi High Technologies America, Inc., California, U.S.) at an 
accelerating voltage of 75kV. Several images were taken of each tissue sample at 5,000 and 
20,000 magnifications, six were chosen from each sample on which to carry out stereological 
analysis.
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The volume of smooth muscle cells was estimated using a variation of the “Nucleator” 
principle as described in (Dockery et al., 1997). Twenty smooth muscle cells were chosen 
from images of each animal at final magnification x310. The profile of each smooth muscle 
cell was traced and a 4-way nucleator applied. The distance from the nucleous of the cell to 
the cell membrane was measured. This was cubed and the mean multiplied by 47T/3, to give 
an estimate of the individual cell volumes. This gave an estimate of the number-weighted 
mean smooth muscle cell volume for each animal in all groups (Dockery, Tang et al. 1997). 
Surface density (Sv) of rough endoplasmic reticulum in smooth muscle cells was estimated 
using an intersect measuring technique on images at a final magnification x 34,560. A 
stereological grid was applied to the images in a random orientation. By counting all 
intersects hitting the object of interest and applying the formula:
Sv = 2 x/L
where /  = the number of intersects and L = the total length of test line applied (Dockery et al., 
1991), an unbiased estimate of rough endoplasmic reticulum in smooth muscle cells was 
determined.
Vv RER: cell (where Vv rER: cell is the volume fraction of rough endoplasmic reticulum as 
compared to the volume of the cell) of smooth muscle cells was estimated on images at a 
final magnification of x34s560 by randomly applying a stereological grid onto the images 
using a simple point counting method and the formula:
V v  = P (rER) (cytoplasm )
where P(RER) was the points that hit the cistemae of rough endoplasmic reticulum and 
P(cytoplasm) was the points that hit the cytoplasm of SMC (Mayhew 1991). Vv Nucleus : 
cell (where Vv Nucleus: cell is the volume fraction of the nucleus as compared to the volume
Stereological parameters investigated from images obtained by TEM
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of the cell)of smooth muscle cells was estimated on images at a final magnification of *8,640 
by randomly applying a stereological grid onto the images using a simple point counting 
method and the formula:
Vv = P (nucleus) (cell)
Where P(nucleus) was the number of test points falling on the smooth muscle cell nucleus 
and P(cell) was the number of test points falling on the smooth muscle cells. (Mayhew 1991) 
Because the volume of the smooth muscle cells was known it was possible to estimate the 
absolute mean surface area (SA) of rough endoplasmic reticulum and the absolute mean 
volume of rough endoplasmic reticulum in smooth muscle cells.
Absolute (surface area) of rough endoplasmic reticulum in smooth muscle cells was 
estimated by multiplying the Vv rough endoplasmic reticulum in smooth muscle cells by the 
volume of the smooth muscle cell.
Absolute volume RER in smooth muscle cells was estimated by multiplying the Sv rough 
endoplasmic reticulum in smooth muscle cells by the volume of the smooth muscle cells.
2.2 Ethical approval and animal care
A genetically modified murine model of Marfan syndrome accurately replicates 
aneurysmal disease of the thoracic aorta. The animals were survived for 8 months from 
birth. Mice with this mutation remain asymptomatic during this period with an extremely 
low rate of dissection or rupture of the aorta. Using a model with this level of 
sophistication facilitates using a smaller number of animals, as each affected animal will 
have a more predictable natural history. This in turn means that a lower number of 
animals are required to observe potential therapeutic benefits. Multiple modalities of 
measurements, including non-invasive measurements were employed, which has the
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effect of further reducing the number of animal required. Non-invasive measurements 
also mean less discomfort to the animals during the study. Procedures were conducted 
with anaesthesia expertise provided by small animal veterinarians, to ensure the highest 
levels of animal care.
All animals were housed in a licensed biomedical research facility (Royal College of 
Surgeons in Ireland, Department of Surgery, Beaumont Hospital) and all procedures were 
carried out under license from the Department of Health and Children, Ireland. Ethical 
approval was obtained from the Royal College of Surgeons in Ireland Research Ethics 
Committee. Appendix 1:1. Ethical approval, contains a copy of the letter from the Royal 
College of Surgeons in Ireland Research Ethics Committee granting ethical approval, 
code REC 099, providing institutional support for the ethical considerations in relation to 
the use of animals in this research study. An extension to this approval was sought from 
the committee.
2.3 Statistical Analysis
Statistical analysis was conducted by using the software package: StatsDirect statistical 
software version 2.7.8, (Cheshire, U.K.). Statistical analysis included, Analysis of 
Variance, ANOVA, with Bonferonni comparisons, (used to compare the means of two or 
more groups), generate p-values, estimate standard error of the mean, medians, 
interquartile ranges and confidence intervals. The statistical package was also used to 
graph these statistics. The threshold for statistical significance used in these studies was p 
< 0.05.
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Natural history of Marfan syndrome
3.1 Introduction
As discussed, Marfan syndrome is a multi-system disease. The most life threatening of 
these is related to aortic pathology. The aorta progressively dilates, eventually becoming 
aneurysmal. This aneurysmal aorta then is at a greatly increased risk of rupture or 
dissections, both of which have an extremely high mortality and if one survives, a 
significant morbidity. This poor survival was demonstrated in a series of 257 patients 
with Marfan syndrome, published in 1972. The average age of death for the 72 deceased 
patients was 32 years. 80% of the known causes of death were due to aortic dilatation and 
its consequences.(Murdoch, Walker et al 1972) A study published in 1989 showed that 
one third of patients who had not yet undergone surgery, had evidence of aortic 
dissection when cardiac catheterization was conducted.(Marsalese, Moodie et al 1989) 
This same study showed that 61% of known deaths were due to aortic dissection or 
rupture or sudden cardiac death.(Marsalese, Moodie et a l 1989) The tissue of the aorta 
itself may be diseased (which may either cause or be a result of the aneurysm). The 
aneurysm occurs at the level of the sinotubular junction. (Shores, Berger et a l 1994) This 
is the area where the coronary arteries originate, at the most proximal part of the aorta, 
the aortic root.
Chapter 3
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Sinotubular junction
Aortic valve leaflets -3 ) Sinotubular junction
Aortic annulus
flet
C
Figures 3.1 A,B & C: Photographs (A&B) and diagram (C) displaying anatomical 
relationship of the sinotubular junction and aortic annulus to the aortic valve 
leaflets.(Lansac 2007)
Aneurysmal dilatation of the aortic root then has a secondary effect on the aortic annulus. 
As the aortic root dilates, so too does the aortic annulus.(Finkbohner, Johnston et al. 
1995) The aortic annulus is the structure which supports the aortic valve. With 
progressive dilation of the aortic annulus, the aortic valve leaflets fail to coapt (aortic 
valve leaflets fail meet in the middle). The aortic valve becomes incompetent. When the 
valve is incompetent, the end diastolic volume within the left ventricle increases. The 
Frank-Starling Law of the heart(Starling and Visscher 1927) states that the greater the 
volume of blood entering the heart during diastole (end-diastolic volume), the greater the
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volume of blood ejected during systolic contraction (stroke volume) and vice-versa. This 
facilitates synchronization of the cardiac output with venous return.
LVEDP (mmHg)
Figure 3.2: The Frank-Starling relationship showing the effects of heart failure 
(ventricular systolic dysfunction, loss of inotropy) on stroke volume and ventricular 
preload (left ventricular end-diastolic pressure, LVEDP). Point A, control point; 
Point B, ventricular failure.
Figure 3.3: Schematic diagram of a single sarcomere: (above) in relaxation, with 
area of overlap outlined in red, of actin and myosin filaments; (below) shortened 
during contraction.
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As the left ventricle fills with more blood than usual, the force of each contraction of the 
cardiac muscle increases. This is because each cardiac muscle fibre experiences an 
increased load. Stretching of the cardiac muscle fibre augments cardiac muscle 
contraction by increasing the affinity of troponin C for calcium. This causes a greater 
number of actin-myosin cross-bridges to form within the muscle fibres. The force that 
any single cardiac muscle fibre generates is proportional to the initial sarcomere length 
(also known as preload), and the stretch on individual fibres is related to End Diastolic 
Volume of the ventricle. The optimal initial length of the sarcomere is 1.6 to 2.2 \im. 
With increasing end diastolic volume, secondary to aortic incompetence, there is less 
overlap of the thick and thin filaments and so a less forceful contraction. This will in turn, 
further increase End Diastolic Volume within the Ventricle (left ventricle in this case). 
The cardiac muscle is shifted to far left, on the Frank-Starling Curve and results in 
continued strain and progressive dilation of the left ventricle. Over time the left ventricle 
which continues to function inefficiently, cannot accommodate to changes in demand and 
starts to fail. On the subcellular level, this phenomenon might be explained by a failure of 
the myofibrils to increase the Ca2+ sensitivity after an increase of the sarcomere 
length(Schwinger, Bohm e ta l  1994).
On a cardiovascular level, as left ventricular pressure decreases in diastole below aortic 
pressure, the aortic valve is not able to close, the regurgitant fraction, regurgitates back 
through the aortic valve and causes a decrease in the diastolic blood pressure in the aorta. 
The sympathetic nervous system via the renin-angiotensin-aldosterone axis of the kidneys 
compensates for reduced cardiac output. As diastolic pressure is reduced systolic blood 
pressure is normalized and sometimes elevated. Catecholamines increase heart rate and
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contractility, thereby increasing cardiac output. Chronic aortic regurgitation causes 
cardiac remodelling with resultant heart failure. Concentric left ventricular hypertrophy is 
due to the increased left ventricular systolic pressures associated with aortic regurgitation. 
Eccentric hypertrophy is due to volume overload caused by the regurgitant fraction. The 
patient experiences increased dyspnoea, orthopnoea, paroxysmal nocturnal dyspnoea and 
fatigue. The patient may also experience wheezing or “cardiac asthma.”(Fishman 1989)
Figure 3.4: Illustration of regurgitant flow of blood through an incompetent aortic 
valve.
The timing and severity of which these events occur can vary from patient to patient. This 
can range from a slow, progressive left ventricular failure secondary to aortic 
incompetence to an acute aortic dissection, with no way to accurately predict which 
pattern will affect each patient. Patients require serial echocardiography and assessment 
of the aortic root diameter.
In order to improve medical management of patients who have Marfan syndrome and to 
develop new strategies to attenuate, slow or ameliorate disease progression, a complete
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understanding of the pattern, timing and underlying mechanisms of disease is of vital 
importance.
Historically, because fibrillin-1 is present in tissues affected by Marfan syndrome, it was 
considered that the underlying defect in fibrillin-1 led to a primary structural weakness in 
this connective tissue protein. Because of recent discoveries, this concept has come into 
question. Transforming Growth Factor beta (TGF-p) dysregulation has become central to 
the current concept of the underlying mechanism of disease and proposed treatment. 
However, the mechanism of disease has yet to be completely defined.
The aim of this research therefore was to establish the pattern, extent, timing and other 
aspects of the underlying mechanism of disease in a model extensively described in the 
literature as suitable for the study of Marfan syndrome.
3.2 Materials and Methods
A pair of male C1039G Marfan mice was cross bred with C57B16 females. Genetic 
analysis of the offspring was conducted. Male mice identified to have the C1039G 
mutation were entered into the study. Thirty-five C1039G mice were entered into the 
natural history group. Forty-five normal, “C57 black 6 mice”, were entered into the study 
for comparison.
The protocol used was based on the literature descriptions of the models used in Johns 
Hopkins University. Each animal received food and water ad-libitum. Aortic root 
diameter was assessed in-vivo, at 3 months and 8 months for evidence of established of 
progression of aneurysmal dilatation, by trans-thoracic echocardiography as outlined in 
the materials and methods chapter. Aortic root pathology was assessed histologically
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using haematoxylin and eosin staining and Verhoeff-von Gieson staining. Animals were 
euthanized. Samples of aortic root were harvested at sequential periods for histological 
examination.
Animals were separated into ten groups, five groups of normal mice and five groups of 
Marfan mice. One group from each was euthanized at 6 weeks, 3 months, 4.5 months, 6 
months and 8 months. Aortic root thickness was assessed with Haematoxylin and Eosin 
staining. Architecture of the aortic media at the level of the aortic root was assessed by 
staining sections with Verhoeff-von Gieson stain. The aortic wall architectural score is 
based on number of islands of damage, per full aortic root cross section. An island of 
damage is defined as an area where there are two or more disrupted elastic lamellae with 
associated thickening of the aortic media.
Table 3.1: Schedule for histological analysis to assess natural history of aortic 
disease in Marfan syndrome with comparison to normal aortic tissue.
Time point 6 weeks 3 months 4.5 months 6 months 8 months
Haematoxyli 
n and Eosin
Normal(n=5
)Marfan(n=5)
Normal(n=5
)Marfan(n=5)
Normal(n=5
) *Marfan(n=5)
Normal(n=5
)Marfan(n=5)
Normal(n=5
)Marfan(n=5)
Verhoeff von 
Gieson
Normal(n=5
)Marfan(n=5)
Normal(n=5
)Marfan(n=5)
Normal (n=5 
)Marfan(n=5)
Normal (n=5 
)Marfan(n=5)
Normal(n=5
)Marfan (n=5)
Cardiac function was assessed using haemodynamic variables cardiac catheter recordings 
of dP/dt maximum as a measure of left ventricular systolic function at 8 months. The
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model used is too small and the technique too demanding to assess this measurement at 
earlier time points.
Aortic valve function was assessed using catheter recordings of systolic and diastolic 
blood pressure at eight months. Assessment of the dicrotic notch was made by measuring 
dP/dt maximum of the downslope of the aortic trace (immediately after the peak systolic 
pressure and before the minimum diastolic value reached).
Samples of aortic root were harvested at 8 months for ultra-structural examination with 
electron microscopy. Measurements of aortic vascular smooth muscle cells were taken. 
The volume of rough endoplasmic reticulum was measured. The volume of the cistemae 
within the Golgi-apparatus was measured. The volumes of mitochondria were also 
measured.
3.3 Results
Results are followed by +/- standard error of the mean in brackets.
3.3.1 Aortic Root Dia meter
Aortic root diameter was measured using trans-thoracic echocardiography. In the group 
containing normal mice (n= 20), the mean aortic root diameter grew from 0.132 (+/- 
0.001) cm at 3 months to 0.161(+/-0.001) cm at 8 months (Figure 3.5). This is an increase 
of 0.0287(+/-0.004) cm over the 5 month period, a 21.7% increase in the aortic root 
diameter. The mean aortic root diameter of the group of Marfan mice, 0.165 (+/- 0.002) 
cm, was already enlarged when measured at 3 months of age. This was an increase of 
0.033cm compared to the mean of the normal group at the same age (Figure 3.5). The
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average aortic root diameter in the Marfan group was increased by 25%, when compared 
to the normal group. Therefore, this model of Marfan syndrome had established dilatation 
of the aortic root at 3 months of age. The mean aortic root diameter increased with 
growth of the mice, in the normal group to 0.161(+/-0.001) cm at 8 months. This was an 
average increase of 0.0287cm, or 21.7% in this group. This would be considered normal 
growth.
The mean aortic root diameter in the Marfan group was increased from 0.165(+/-0.001) 
cm at 3 months to 0.252(+/-0.004) cm at 8 months (Figure 3.5). This was an increase of 
0.0869cm, or 53.9% in the mean aortic root diameter over the 5 month period. Compared 
to the normal group at 8 months, the mean aortic root diameter was 0.091cm larger, or 
56.5% larger than the normal group (p<0.0001).
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Aortic root diameter(cm) Normal versus 
Marfan at 3 & 8 months
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Figure 3.5: Comparing Normal & Marfan Aortic root diameter (cm) at two time- 
points, 3 and 8 months.
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3.3.2 Cardiac catheterization results
Left Ventricular dP/dt max
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dP/dt max (mmHg/sec)
Figure 3.6: Left ventricular dP/dt max, comparing mean values of normal and of 
Marfan groups.
There was a reduction in the left ventricular dP/dt maximum in the Marfan group, 
4793(+/- 172.6) mmHg/sec, when compared with the normal group, 6574 (+/-257.3) 
mmHg/sec, (p < 0.0001), (Figure 3.6). This was a 27% reduction in contractility. This is a 
statistically significant result.
As discussed previously in this chapter in relation to the Frank-Starling mechanism, 
changes in filling pressure or pre-load secondary to anaesthesia, will affect cardiac 
contractility. There are a number of factors contributing to variation in subject to subject 
pre-load, such as hydration status, response to anaesthetic, depth of anaesthesia and 
vascular tone (which could relate to pharmaceutical therapy). In an attempt to normalise 
for this we calculated the left ventricular contractility index. The left ventricular
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contractility index is the left ventricular dP/dt max divided by the left ventricular end 
diastolic pressure.
Marfan
Normal
Left ventricular contractility index, 
comparing normal to Marfan values
— I— >— 1— ■— «— I—
2000 4000
— I------1------- 1-------1-------1-------1
6000 8000
min -f mean ± 95% confidence interval}- max
Left ventricular contractilitv index
Figure 3.7: Left ventricular contractility index, comparing Normal to Marfan 
Values.
The mean contractility index for the normal group is 876(+/-129.9). The mean 
contractility index for the Marfan group is 957(+/-102.9), (Figure 3.7). The p-value for 
comparison between the two groups is 0.62, which shows that there is no statistical 
difference, between the two for this variable. In both Figures 3.6 and 3.7 the range is 
broad in both groups and this affects statistical significance negatively. Anaesthesia using 
a combination of Ketamine and Xylazine is well known to be one of the most reliable for 
inducing relaxation, sedation and analgesia in mice when assessing cardiac
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function.(Hart, Burnett et al. 2001) Unfortunately it is also well known for inducing 
bradycardia. Bradycardia would affect left ventricular dP/dtmax and would be a variable 
which would increase the range of measurements taken. In an attempt to control for 
variability of left ventricular dP/dtmax, the left ventricular contractility index was 
calculated, though the range of measurements remains high (Figure 3.7).
Pulse Pressure
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Figure 3.8: Comparing Average aortic pulse pressure between Normal and Marfan 
Groups. The aortic diastolic pressure is noted in blue, with the aortic systolic 
pressure noted by red, with pulse pressure documented within the red section of 
histogram. Lines joining systolic and diastolic values convey their similarity.
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The mean pulse pressure for the normal group is 40.7 (+/- 0.66) mmHg and the mean for 
the Marfan group is 39.7 (+/- 1.13) mmHg, (Figure 3.8). There is very little difference in 
the pulse pressure between the two groups. ImmHg would not be clinically significant 
even if it was statistically significant.
Analysis of the Aortic dicrotic notch.
The aortic pulse has a positive inflection after peak systolic pressure during diastole. It is 
caused by the rebound impulse due to the closure of the aortic valves.
The maximum slope of the down-stroke of the aortic pressure waveform following peak 
systolic pressure was measured. A positive result when the maximum slope was 
measured reflected a positive inflection (which represents a change in pressure secondary 
to aortic valve coaptation), (Figure3.9). A negative result when the maximum slope was 
measured, reflected an absence of a positive inflection (which may represent a failure of 
effective aortic valve coaptation) and so identified the presence of aortic incompetence 
(Figure 3.10). The presence of aortic insufficiency (incompetence) may be the cause of a 
reduction in left ventricular dP/dt max.
Table 3.2: Comparison of the aortic dicrotic notch in Marfan and normal aortic 
pressure tracing
iteüä) V m m ¡flags
Normal 0 20 0%
Marfan 8 22 36.4%
The aortic valve was competent in all normal controls, as the aortic notch was present in 
all twenty of the group, (Table 3.2). Aortic incompetence was present in 36.4% of aortic 
pressure tracings taken in untreated Marfan mice, (Table 3.2).
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Figure 3.9: Aortic pressure trace, taken with Millar pressure transducer. It shows 
the aortic pulse pressure with aortic dicrotic notch, present on down-stroke of wave 
form and identified with an X.
Figure 3.10: Aortic pressure trace, taken with Millar pressure transducer. It shows 
the aortic pulse pressure with absence of the aortic dicrotic notch, which is normally 
present on down-stroke of wave form (yellow circle).
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3.3.3 Histology
Marfan groups
Figure 3.11: Natural history of aortic wall thickness (pm) comparing normal to 
Marfan at different time-points. N = 60. Mean standard deviation of normal group = 
14.4jim and Marfan group = 60.7jim. There is a fluctuation in the trend at 4.5 
months.
One of the values for aortic wall thickness in the 4.5 month group was more than 3 
standard deviations outside the mean for the rest of the values (Figure 3.11). This one 
observation was removed from the data, to gain more meaningful information from the 
groups (Figure 3.12).
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Marfan groups
Normal groups
Figure 3.12: Natural history of aortic wall thickness (fim) comparing normal to 
Marfan at different time-points (with outlier removed). N = 59. Mean standard 
deviation of normal group = 14.4^m, and Marfan group = 31.5fim.
By removing one outlier from the 4.5 month group, the graph shows an overall increase 
in the aortic wall thickness with age in both groups. The marfan groups have consistently 
higher values at each time point, with p < 0.01 when an analysis of variance with 
Bonferroni corrections.
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Table 3.3: Aortic wall thickness in normal & marfan subjects at consecutive time- 
points (without outlier).
The aortic wall was thinnest at 6 weeks in both groups. The mean aortic wall thickness in 
normal subjects increased from a low of 64.69 pm (+/-5.2), to its thickest at 8 months of 
109.85 pm (+/-6.1) (Table 3.3). It rose steadily, following an initial elevated value of 
91.99 pm (+/- 10.5), rising from 84 pm at 4.5 months, 96 pm (+/- 8.4) at 6 months & 
finally 109 pm (+/- 6.1) at 8 months. The aortic wall in Marfan syndrome was thicker 
than normal aorta wall at 6 weeks, 98.6 pm (+/- 7.7). In fact it is 53% thicker than 
normal at this stage. There was again an initial elevation of the value at 3 months, 117 pm 
(+/- 15.9). After this the trend rose from the 6 week value to 108.5 pm (+/- 21) at 4.5 
months, 106 pm (+/- 17.1) at 6 months to the thickest value of 151 pm (+/- 7.7) at 8 
months. The marfan aortic wall was thicker than normal aortic wall at every time-point 
measured. At 8 months, the wall was 38% thicker than normal. The aortic wall was found 
to be significantly thickened at the earliest time-point measured (6weeks), and this trend 
followed as the aortic wall grew in the normal context, so too did the marfan aorta, 
though with ongoing, significant thickening (Figure 3.12). This thickening was 
pathological, as with more thickening, the aortic wall became less compliant.
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Marfan groups
Normal groups
Measure of architectual integrity
Aortic wall architecture, normal versus 
marfan at consecutive time-points
6 weeks 3 months 4.5 months 6 months 8 months
Age (months)
Figure 3.13: Natural history of aortic wall architecture, comparing normal to 
Marfan at different time-points. N = 53. Mean standard deviation, of normal group 
= 0.79, and Marfan group = 10.1. There is a fluctuation in the trend at 3 months.
There was one value in the 3 month group which lay more than 3 standard deviations 
outside the mean for the rest of the values (Figure 3.13). By removing this outlier, a
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different mouse than in discussed in relation to aortic wall thickness (figure 3.11), the 
data was more representative. The graph now looks like Figure 3.14.
Marfan groups 
Normal groups
Aortic wall architecture, normal versus 
marfan at consecutive time-points
Figure 3.14: Aortic wall architecture, normal versus marfan at consecutive time 
points, with outlier removed from the data. N = 52. Mean standard deviation, of 
normal group = 0.79, and Marfan group = 8.5. The graph shows an overall increase 
in the aortic wall thickness with age in both groups. The marfan groups have 
consistently higher values at each time point.
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The aortic wall architecture was assessed at 5 different time-points, in each group. In the 
normal group showed consistently low architectural scores, starting a 0.25 (+/- 0.25) at 6 
weeks, 0 at 3 months, 0.6 (+/- 0.4) at 4.5 months and 6 months, then rose slightly to 1.2 
(+/- 0.49) at 8 months, (Figure 3.14). On the other hand, the 6 week marfan group 
showed an initial score of 2.4 (+/- 1.9), which was significantly higher than normal at 
this time point. There was a sharp rise between 6 weeks and 3 months in the marfan 
group, with the architectural score rising to 9 (+/- 3). This was a 3.75 fold rise from an 
already elevated value at 6 weeks. A lot of damage had taken place at this stage. The 
values then rose very slowly to 9.2 (+/- 4.3) at 4.5 months and 9.8 (+/-6) at 6 months. 
There was a further steep rise to 13 (+/- 2.6) at 8 months in this marfan group. This was 
10.8 times the value of the normal group at this age. Overall, the two patterns were 
widely disparate with the normal group having consistently low values and the marfan 
group rising quickly, remaining elevated and continuing to rise, (Figure 3.14).
72
Elastin Volume
Elastin volume at 8 months
Figure 3.15: Mean elastin volume as a proportion of the aortic wall at 8 months in 
normal and Marfan groups. This shows that elastin volume is greatly reduced in the 
Marfan group compared with the normal group.
Elastin volume was 0.271 (+/- 0.02) of the aortic wall, where Marfan aortic wall 
thickness had a greatly reduced level of elastin at 0.1858 (+/- 0.01), (Figure 3.15). 
Despite a range in values, there remains a statistically significant difference between the 
two groups, p = 0.0143. The loss of elastin in the Marfan group was associated with a 
high degree of architectural damage seen at eight months in the Marfan group.
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3.3.4 Electron-microscopy of Aortic Wall
Figure 3.16: Transmission electron micrograph of a uranyl acetate and lead citrate 
stained resin section of the tunica media showing concentric bands of elastic 
lamellae (white arrow) interspersed with SMCs (black arrow). Tissue: normal 
mouse aortic root. Scale bar: 10 pm.
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Figure 3.17: Transmission electron micrograph of a uranyl acetate and lead citrate 
stained resin section of a SMC (black arrow), lying between two elastic lamellae 
(white arrow). Tissue: normal mouse aortic root. Scale bar: 2 pm.
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Figure 3.18: Transmission electron micrograph of a uranyl acetate and lead citrate 
stained resin section of a SMC with small amount of RER (white arrow) and 
mitochondria (black arrow) in cytoplasm, lying beside an elastic lamella (blue 
arrow). Tissue: normal mouse aortic root. Scale bar: 500nm.
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Figure 3.19: Transmission electron micrograph of a uranyl acetate and lead citrate 
stained resin section showing an intact internal elastic lamella (white arrow) above a 
fragmented elastic lamella (blue arrows), with interspersed SMCs (black arrow) 
within the tunica media. Tissue: Marfan mouse aortic root. Scale bar: 10pm.
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Figure 3.20: Transmission electron micrograph of a uranyl acetate and lead citrate 
stained resin section showing the tunica media with a broken internal elastic lamella 
(blue arrows) and disorganised SMCs (black arrows). Tissue: Marfan mouse aortic 
root. Scale bar: 5jim.
In figure 3.20, loss of the tunica intima is observed. This could be an artefact in relation 
to slide preparation, though impairment of the tunica intima has been observed with 
vacuolisation, thinning, intercellular Assuring and loss of function of this 
layer.(Sheremet'eva, Ivanova et al 2004)
I
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Figure 3.21: Transmission electron micrograph of a uranyl acetate and lead citrate 
stained resin section showing a SMC with RER (white arrow) and elastic fibre (blue 
arrow). Tissue: Marfan mouse aortic root. Scale bar: 2pm.
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Figure 3.22: Transmission electron micrograph of a uranyl acetate and lead citrate 
stained resin section of a SMC (black arrow) attached to elastic fibre (white arrow). 
Tissue: Marfan mouse aortic root. Scale bar: 500nm.
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Figure 3.23: Transmission electron micrograph of a uranyl acetate and lead citrate 
stained resin section of a SMC with cell nucleus (white asterisk) surrounded by RER 
(white arrow) and mitochondria (black arrow). Tissue: Marfan mouse aortic root. 
Scale bar: 500nm.
Assessment of intra-nuclear activity by ultrastuctural examination with electron 
microscopy
Euchromatin is a lightly packed form of chromatin (DNA, RNA and protein) that is rich 
in gene concentration, and is often (but not always) under active transcription. 
Euchromatin participates in the active transcription of DNA to mRNA products. The 
unfolded structure allows gene regulatory proteins and RNA polymerase complexes to 
bind to the DNA sequence, which can then initiate the transcription process. Not all
euchromatin is necessarily transcribed, but in general that which is not is transformed into 
heterochromatin to protect the genes while they are not in use. There is therefore a direct 
link to how actively productive a cell is and the amount of euchromatin that can be found 
in its nucleus. It is thought that the cell uses transformation from euchromatin into 
heterochromatin as a method of controlling gene expression and replication, since such 
processes behave differently on densely compacted chromatin, known as the 
“accessibility hypothesis”. One example of constitutive euchromatin that is “always 
turned on” is housekeeping genes, which code for the proteins needed for basic functions 
of cell survival. Euchromatin comprises the most active portion of the genome within the 
cell nucleus.
When the mean volume of euchromatin was measured (of the aortic smooth muscle cell 
nucleus) there was no statistical difference between normal, 0.59 (+/- 0.01) and Marfan 
nuclei, 0.61 (+/- 0.01). When the mean levels of heterochromatin were measured, of the 
aortic smooth muscle cell nucleus, there was no statistical difference between normal, 
0.318 (+/- 0.02), and Marfan, 0.298 (+/- 0.01). P-values are > 0.4 in these cases.
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Figure 3.24: Electron photomicrograph of a nucleus of an aortic smooth muscle cell
showing euchromatin (black arrow) and heterochromatin (white arrow).
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Figure 3.25: Diagram of a nucleus of cell showing euchromatin and
heterochromatin. (Diagram by Mariana Ruiz Villarreal, permission granted by 
artist)
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The nucleolus (also called nucleole) is a non-membrane bound structure composed of 
proteins and nucleic acids found within the nucleus. Ribosomal RNA (rRNA) is 
transcribed and assembled within the nucleolus. The nucleolus ultra-structure can be 
visualized with an electron microscope. There is no statistical difference between the 
mean volume of the nucleolus (as a proportion of the nucleus), in the normal aortic 
smooth muscle cell (0.0846) and the Marfan aortic smooth muscle cell (0.0853).
Figure 3.26: Electron photomicrograph of an aortic smooth muscle cell showing a
nucleus (black arrow) and nucleolus (white arrow) within.
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Figure 3.27: Nuclear & Nucleolar data, normal and Marfan groups at 8 months. 
Heterochromatin volume (as a proportion of the nucleus) in Marfan group is similar 
to normal Euchromatin volume (as a proportion of the nucleus) in Marfan group is 
similar to normal. Nucleolar volume (as a proportion of the nucleus) in Marfan 
group is similar to normal.
Mitochondria are a membrane-enclosed organelle found in most eukaryotic cells. These 
organelles range from 0.5 to 10 micrometers (jim) in diameter. Mitochondria are 
sometimes described as "cellular power plants” because they generate most of the cell's 
supply of adenosine triphosphate (ATP), used as a source of chemical energy. In addition 
to supplying cellular energy, mitochondria are involved in a range of other processes,
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such as signalling, cellular differentiation, cell death, as well as the control of the cell 
cycle and cell growth. Mitochondria have been implicated in several human diseases, 
including mitochondrial disorders and cardiac dysfunction.
Figure 3.28: Electron photomicrograph of cell organelles within an aortic smooth 
muscle cell. Mitochondria are present; one mitochondrion is displayed by a white 
arrow.
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As noted in a prior electron-microscopy study of Marfan aorta, we also noted in our study 
that there were an increased amount of mitochondria in the aortic smooth muscle cells in 
Marfan aortic smooth muscle compared to normal aortic smooth muscle. (Scheck 1979) 
The volume of mitochondria as a proportion of the cytoplasm was increased in Marfan 
aorta, 0.108 (+/- 0.01), as compared to normal aortic tissue, 0.07 (+/- 0.01). Though the p 
= 0.089, it comes close to statistical significance. The number of individual mitochondria 
was not quantified separately, as a stereological technique was used to measure the 
volume of the cell and the volume of which contained mitochondria. The number of 
mitochondria could be estimated from the volume of mitochondria per cell, though the 
accuracy of this calculation has not been validated.
Mitochondrial volume within aortic smooth muscle cells
Vv Mito:Cyto Marfan
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Mean mitochondrial volume as a proportion of aortic 
vascular smooth muscle cells
0.19
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Figure 3.29: Mean mitochondrial volume as a proportion of aortic vascular smooth 
muscle cells. A comparison between normal and Marfan aortic root tissue.
Rough Endoplasmic Reticulum, as a proportion of the cytoplasm was greatly increased in 
Marfan groups, 0.0346, compared to normal groups, 0.0091, (p = 0.0005), which is 
displayed in the graph below. The difference in smooth endoplasmic reticulum 
approached significance at p = 0.06, though unexpectedly extremely small volumes were 
noted in the normal group, the value measure was equal to zero. The Marfan group, 
0.0016, also had very small volumes.
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Figure 3.30: Electron photomicrograph of cell organelles within an aortic smooth 
muscle cell from the normal, control group. Rough Endoplasmic Reticulum are 
present, one area displayed by a white arrow.
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Figure 3.31: Electron photomicrograph of cell organelles within an aortic smooth 
muscle cell from the Marfan group. Rough Endoplasmic Reticulum is present, one 
area displayed by a white arrow and other areas encircled in pink.
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Figure 3.32: Mean volume of rough Endoplasmic Reticulum compared to smooth 
Endoplasmic Reticulum, as a proportion of normal or Marfan aortic vascular 
smooth muscle cytoplasm.
There was almost no Golgi apparatus measured as a proportion of the aortic smooth 
muscle cytoplasm in the normal group, the value measured was equal to zero. In 
comparison to this, the amount of Golgi apparatus (i.e. the mean volume of Golgi 
apparatus measured as a proportion of the aortic smooth muscle cytoplasm) in the Marfan 
group measured was 0.0016, as a proportion of the cytoplasm (estimated std. error of the 
mean = 0.00071). This did not meet the criteria for statistical significance.
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Figure 3.33: Mean volume of Golgi apparatus measured as a proportion of the 
aortic smooth muscle cytoplasm, normal compared to the Marfan group.
Light microscopy images, of the course of the natural history in normal and Marfan 
aortic root.
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Figure 3.34: Light microscopy image: 
haematoxylin and eosin stained cross- 
section of aortic root of wild-type 
mouse at 6 weeks, magnification xlO.
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Figure 3.35: Light microscopy image: 
haematoxylin and eosin stained cross- 
section of aortic root of wild-type 
mouse at 3 months, magnification x40.
Figure 3.36: Light microscopy image: 
haematoxylin and eosin stained cross- 
section of aortic root of wild-type 
mouse at 3 months, magnification x20.
Figure 3.37: Light microscopy image: 
haematoxylin and eosin stained cross- 
section of aortic root of wild-type 
mouse at 4.5 months, magnification 
x40.
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Figure 3.38: Light microscopy image: 
haematoxylin and eosin stained cross- 
section of aortic root of wild-type 
mouse at 6 months, magnification x40.
Figure 3.39: Light microscopy image: 
haematoxylin and eosin stained cross- 
section of aortic root of wild-type 
mouse at 8 months, magnification x40.
Figure 3.40: Light microscopy image: 
haematoxylin and eosin stained cross- 
section of aortic root of wild-type 
mouse at 8 months, magnification x40.
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Figure 3.41: Light microscopy image: 
haematoxylin and eosin stained cross- 
section of aortic root of “Marfan” 
mouse at 6 weeks, magnification xlO.
Figure 3.42: Light microscopy image: 
haematoxylin and eosin stained cross- 
section of aortic root of “Marfan” 
mouse at 6 weeks, magnification xlO. 
Aortic valve cusp present (black 
arrow).
Figure 3.43: Light microscopy image: 
haematoxylin and eosin stained cross- 
section of aortic root of “Marfan” 
mouse at 3 months, magnification xlO. 
Early evidence of aberrant aortic wall 
is present.
95
Figure 3.45: Light microscopy image: 
haematoxylin and eosin stained cross- 
section of aortic root of “Marfan” 
mouse at 6 months, magnification xlO. 
Evidence of progressive aberrant 
aortic wall thickening is present 
(yellow arrows).
Figure 3.44: Light microscopy image: 
haematoxylin and eosin stained cross- 
section of aortic root of “Marfan” 
mouse at 4.5 months, magnification 
xlO. Loss of usual arrangement of 
elastin is evident (black circle).
Figure 3.46: Light microscopy image: 
haematoxylin and eosin stained cross- 
section of aortic root of “Marfan” 
mouse at 8 months, magnification xlO. 
Thickened aortic wall is evident with 
loss of the uniform vascular smooth 
muscle cell arrangement.
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Light microscopy images of haematoxylin and eosin stained cross-sections of normal 
murine aortic wall, at the level of the aortic root, are shown in figures 3.34 to 3.39. They 
display the change in the appearance of the aortic wall through the course of development 
from 6 weeks (figure 3.34), 3 months (figure 3.35 & 3.36), 4.5 months (figure 3.37), 6 
months (figure 3.38) and at 8 months (figure 3.39 & 3.40). The normal aorta, at the level 
of the aortic root, has to accommodate an ever increasing circulating volume of blood as 
the mouse develops and grows. The larger volume of blood is accommodated by 
increasing the diameter of the aorta, which is evident in figures 3.34 to 3.40. By referring 
to the law of La Place, the greater the radius of the vessel, the greater the transmural 
pressure across the wall. The wall develops and becomes slightly thicker to accommodate 
to the tension on the wall of the vessel, from having tightly compact elastin fibres with 
little space in between fibres, at 6 weeks (figure 3.34) and 4.5 months (figure 3.37), to 
developing a slightly thicker appearance with more substantial space between the fibres at 
6 (figure 3.38) and 8 months (figure 3.40). Throughout the course of development we can 
see the smooth uniform arrangement of smooth muscle cells between the elastin fibres 
remains a feature.
In contrast to the normal maturation of the aortic wall, the pathological changes present 
during development of the Marfan aortic wall are displayed in light microscopy images of 
haematoxylin and eosin stained cross-sections of Marfan, murine aortic wall, at the level 
of the aortic root in figures 3.41 to 3.46. At 6 weeks, the elastin fibres are tightly compact 
with a “wavy,” uniform smooth pattern (figures 3.41 and 3.42). There is evidence of early 
abnormal thickening of the aortic wall at 3 months (figure 3.43) and loss of the usual
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uniform arrangement of elastin fibres at 4.5 months (figure 3.44). There is evidence of 
established abnormal thickening of the aortic wall present at 6 months (figure 3.45) and 
this persists at 8 months (figure 3.46).
Figure 3.47: Light microscopy image: Verhoeff-Van Gieson stained cross-section of 
aortic root of “Marfan” mouse at 8 months, magnification xlO. The aortic wall is 
thickened (yellow arrows) with loss of the usual arrangement of elastin (red circle).
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Figure 3.48: Light microscopy image: Verhoeff-Van Gieson stained cross-section of 
aortic root of “Marfan” mouse at 8 months, magnification x20. At a higher 
magnification view, this displays two islands of damage, encircled (yellow).
Light microscopy images of Verhoeff-Van Gieson stained cross-sections of murine 
Marfan aortic root at 8 months, display both aortic wall thickening and loss of the usual 
arrangement of elastin in figure 3.47. A higher power light microscopy image displays 
two areas where there is loss of continuity of, two or more, separate elastin fibres in close 
proximity, also called “islands of damage” (figure 3.48).
Mean values and standard deviations were established for a normal murine aorta root 
diameter at 3 and 8 months. Mean values and standard deviations were also established for a 
murine Marfan model aorta root diameter at 3 and 8 months. The Marfan aortic root were 
found to be dilated by 25% at 3 months and developed aneurysmal disease with a growth rate 
of 53% over a 5 month period. This is similar to the initial studies published by our 
collaborators, showing a 14% increase in the diameter of the aortic root at 7 weeks of age 
between normal and Marfan mice. (Habashi, Judge et al. 2006) There was a 27% increase in 
the size of the aortic root in Marfan mice compared to normal controls at 3 months, in a study 
conducted by Chung et a l (Chung, Yang et a l 2008) The growth rate in our study was 3 
times the growth rate of normal aortic root diameter in Marfan mice, which was similar to 
that of Habashi et #/. (Habashi, Judge et a l 2006) The mean aortic root diameter of Marfan 
mice had aneurysmal aortas 56.5% wider than normal controls at 8 months, which is even 
greater than the 36% difference observed by Habashi et al. (Habashi, Judge et al 2006) and 
the 32% difference seen by Chung et a l  (Chung, Yang et al. 2008) The extent of aneurysmal 
dilatation in this study is comparable to other studies being conducted internationally. 
Myocardial function was assessed in both normal and Marfan groups. Left ventricular 
function can be reduced in Marfan Syndrome prior to established valvular 
disease(Kiotsekoglou, Bajpai et a l 2008). Left ventricular dP/dt maximum was measured and 
shown to be reduced by 27% compared to normal. Using a contractility index of left 
ventricular function did not discriminate between the two groups. In 2003, a cohort of 
patients with Marfan syndrome in the Mayo clinic with no or mild aortic or mitral 
regurgitation, had, in general, no evidence of left ventricular impairment in the absence of 
significant valvular disease.(Chatrath, Beauchesne et a l  2003) Though in 2006, evidence of
3.4 Discussion
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mild but significant impairment of left ventricular systolic & diastolic function, was found in 
a cohort of Marfan patients unrelated to valvular disease.(De Backer, Devos et al. 2006) 
Aortic pulse pressure was measured to assess for evidence of aortic insufficiency. There was 
no clinically significant widening of the aortic pulse pressure in either group. If there was a 
significant widening of the aortic pulse pressure in the Marfan group this would have 
supported evidence of severe aortic insufficiency. (Hamby, Gulotta et al. 1968) The aortic 
dicrotic notch, which reflects failure of coaptation, is a more subtle sign of aortic 
insufficiency.(Hamby, Gulotta et al. 1968) This was present in 36% of the Marfan group. 
This finding would reflect aortic annular dilatation secondary to aortic root dilatation as 
measured by echocardiography, as patients with aneurysms of the ascending aorta or aortic 
root, frequently have aortic valve insufficiency despite having normal valve leaflets.(David, 
Feindel et al. 1995) These results displayed in Figure 3.5 and discussed in Section 3.3.1 
Ongoing aortic insufficiency would cause impairment of left ventricular function. Reduced 
left ventricular function would be reflected by reduced left ventricular contractility. As 
mentioned above, there is evidence of ventricular dysfunction and it is likely that this is 
secondary to aortic insufficiency, though there could be a primary Marfan related 
cardiomyopathy which could be an alternate primary cause. (Alpendurada, Wong et a l 2010) 
Histological analysis showed progressive aberrant thickening of the aortic wall at the level of 
the aortic root. The progressive thickening occurred with a similar pattern to the normal 
growth pattern in the wild-type group. Thickening was found to be established early in the 
disease and continue to develop over the first 3 months of life. There was a second rapid 
increase in thickening from 6 to 8 months after a plateau phase. Other studies have observed 
a similar findings with regard to aortic wall thickness increased by 50%.(Habashi, Judge et 
al. 2006) This was initially thought to be related to a second phase of inflammation, brought 
about by recruitment of neutrophils, as matrix metalloproteinase-9 levels are elevated in
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Marfan aortic root tissue (Ikonomidis, Jones et a l  2006) and Matrix metalloprotease-9 is also 
called neutrophil elastase, and there is growing evidence that it is involved in remodelling of 
vessels. (Dollery, Owen et a l  2003) A neutrophilic infiltrate was not observed in our 
specimens at 8 months. This suggests that, the pathological process maybe, related to an 
ongoing interaction between the aortic vascular smooth muscle cells and the intercellular 
matrix of the aortic wall.
Progressive loss of the architectural integrity of the aortic wall at the level of the aortic root 
was observed in the Marfan group. There was some evidence of disruption of the elastic fibre 
architecture at 6 weeks in the Marfan group. Other groups also found evidence of loss of 
architectural integrity with fragmentation of the elastic lamellae. (Habashi, Judge et al. 2006; 
Chung, Yang et a l  2008) There was a dramatic rise in the amount of “islands of damage” in 
the six week period between 6 weeks and 3 months of age. This was followed by a plateau 
phase, until the period between 6 and 8 months where there was a second rise in the amount 
of disruption. The timing of both aberrant thickening and architectural disruption are similar 
in the Marfan group, suggesting that these are both consequences of the same mechanism. 
Elastin volume was reduced in the Marfan group along with increased elastin disruption. 
Ultra-structural analysis showed no evidence that there was an appreciable difference in the 
amount of nucleus available for transcription as the proportion of heterochromatin or 
euchromatin, within the cell nucleus was unchanged. There was no ultra-structural evidence 
that an overall increased amount of ribosomal RNA was being transcribed, as there was no 
difference between nucleolar size in each group. The amount of rough Endoplasmic 
Reticulum was increased greatly, proving that there is an increased amount of protein 
production within the aortic vascular smooth muscle and this correlates with the histological 
findings and the aortic root dilatation in the Marfan group. Mitochondrial volumes were 
greatly increased in the Marfan group, which reflects greater activity of the cell and they are
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localized close to the rough Endoplasmic Reticulum reflecting the increased activity of the 
rough Endoplasmic Reticulum. The Marfan aortic vascular smooth muscle showed a trend 
toward having an increased volume of rough Endoplasmic Reticulum compared to normal 
aortic vascular smooth muscle cells. The Golgi volume was also increased in the Marfan 
group, which reflects a great amount of transportation of proteins through the cell for 
transport out of the cell. The excessive protein production within the aortic vascular smooth 
muscle cell, is associated with increased transportation of these proteins out of the cell, and in 
turn was associated with histological changes within the aortic wall itself and the overall 
dilatation of the lumen of this structure. Increased prominence of synthetic organelles have 
been noted within aortic vascular smooth muscle cells in a mouse homozygous for a targeted 
hypomorphic allele of fibrillin-1, with prominence of Golgi apparatus, endoplasmic reticulum 
and cytoplasmic vacuoles.(Bunton, Biery et al. 2001)
Observations have been made which are comparable to other studies published to show a 
significant differences between echocardiographic, invasive left ventricular assessment, 
histologic and ultrastructural aspects of Marfan syndrome recapitulated by the C1039G 
Marfan mouse. These results document the natural history and form integral pieces of the 
puzzle in understanding the pathophysiology of Marfan syndrome.
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A comparison of pharmaceutical treatments for attenuation of aortic root pathology in 
Marfan syndrome
4.1 Introduction
As advances in cardiac surgery for the aortic root continue to reduce the morbidity and 
mortality of elective aortic root replacement for patients with aortic root aneurysm, there 
remains a risk to patients of acute aortic rupture or acute aortic dissection of the aortic root 
before prophylactic surgery is completed.(Finkbohner, Johnston et a l  1995) There is also a 
risk of dissection in the remaining native aorta after root replacement.(Smith, Fann et al. 
1994; Pyeritz 2009) If medical management of the disease could be augmented to delay the 
onset of aneurysmal dilatation, to slow the rate of increase of the size of the aortic aneurysm 
or to halt pathological changes with the aortic media, this would be of great benefit to the 
patient. This is especially so for patients with an extreme form of early onset Marfan 
syndrome(Brooke, Habashi et al. 2008) and for women of childbearing years (as aortic 
aneurysms progress rapidly and are at an increased risk of rupture during pregnancy). 
Furthermore, if new medical management with pharmaceutical therapy were highly effective, 
they could potentially reduce the need for surgical management of aortic root dilatation, 
secondary complications and other cardiovascular manifestations.
Over the last three decades there has been a dramatic increase in the life expectancy of people 
with Marfan syndrome.(Pyeritz 2009) This could be further improved upon and indeed their 
quality of life could also be improved as medical management could also attenuate other 
systemic manifestations.
The central role of TGF-p in Marfan syndrome is now widely acknowledged and is providing 
a target for possible protective strategies.(Habashi, Judge et al. 2006; Matt, Habashi et al
Chapter 4
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2008) Effective safe therapies are currently being trialled in an attempt to translate the 
laboratory findings into a highly effective clinical practice.(Lacro, Dietz et al. 2007; Detaint, 
Aegerter e ta i  2010)
4.1.1 Potential mechanism of action of Losartan
There was a breakthrough in the understanding of Marfan syndrome with the study of lung 
disease. TGF-P levels were shown to be elevated in the lung parenchyma of emphysematous 
lung tissue, which is the result of failure of pulmonary septation at an embryonic stage. TGF- 
P antagonism rescued pulmonary alveolar septation. TGF-P antagonism through systemic 
administration of TGF-[beta] neutralizing antibody was then shown to have prevented the 
development of pathological changes in the aortic wall and progressive aortic 
dilatation.(Pereira, Lee et al. 1999; Neptune, Frischmeyer et al. 2003) TGF-p antagonism 
also rescued other manifestations of MFS, including muscle regeneration, architecture, and 
strength, and mitral valve morphology in the mouse model.(Dietz, Cutting et al. 1991; 
Bunton, Biery et al. 2001), Losartan is an angiotensin II type 1 receptor blocker (ARB) which 
is used as an anti-hypertensive agent. It was also found to antagonize TGF-P signalling, 
through inhibition of TGF-p expression and activation, in a study of renal injury in uraemic 
rats.(Lavoie, Robitaille et al. 2005) Administration of Losartan normalized aortic root growth 
and dimensions in the Marfan mouse and resulted in an aortic wall architecture that was 
similar to that of normal mice.(Pereira, Lee et al. 1999) The therapeutic benefit of Losartan 
was recently replicated in a small paediatric cohort with a severe form of MFS.(Dallas, 
Miyazono et al. 1995) Losartan, either alone or in addition to beta-blocker therapy, led to a 
reduction in the rate of change in the aortic root diameter compared with beta-blocker therapy 
alone.(Dallas, Miyazono et al. 1995) Taken together, these data suggest that dysregulation of 
TGF-beta, which is an autocrine and paracrine growth factor with involvement in a wide
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range of biological processes, contributes to the multisystem pathogenesis of Marfan 
syndrome.(Dietz, Pyeritz et a l 1991; Dallas, Miyazono et al. 1995; Pereira, Lee et a l 1999; 
Matt, Schoenhoff et a l  2009)
4.1.2 Potential mechanism of action of Doxvcvcline
Experiments have shown that Doxycycline, a tetracycline class antibiotic, at a sub- 
antimicrobial dose effectively inhibit a broad spectrum of matrix metalloproteinase enzymes 
and suppresses aneurysm formation coinciding with aortic wall stabilization in animal models 
and human aortic aneurysm.(Chung, Yang et al. 2008) Doxycycline has been investigated in 
clinical trials for abdominal aortic aneurysmal disease. (Lindeman, Abdul-Hussien et al
2009) MMP 9 production and elastin degradation were reduced by Doxycycline in a study of 
aortic aneurysms.(Boyle, McDermott et a l 1998) MMP-2 and MMP-9mRNA and protein 
expression were found to be correlated with the size of abdominal aortic aneurysm(Chung, 
Yang et a l  2008) and Doxycycline treatment was associated with a reduction in aortic wall 
expression of MMP-2 and MMP-9. A recent study has shown delayed aortic rupture and 
improved survival in a mouse model of Marfan syndrome with down-regulation of MMP-2&- 
9. However, the beneficial mechanisms of action have not been elucidated.(Xiong, Knispel et 
a I 2008) Doxycycline when given long term was found to be more effective than atenolol in 
preventing thoracic aortic aneurysms in a murine model of Marfan syndrome.(Chung, Yang 
et a l 2008)
4.1.3 Potential mechanism of action of Pravastatin.
Statins are potent inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) and 
thereby affect the mevalonate pathway, which is important for the biosynthesis of isoprenoids 
such as geranylgeranyl pyrophosphate (GGPP) and famesyl pyrophosphate (FPP), as well as 
cholesterol.(Goldstein and Brown 1990) GGPP and FPP are important lipid attachments for
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the posttranslational modification of several proteins that include the small GTP-binding 
proteins Ras, Rac, and Rho. Attachment of these lipids, so-called isoprenylation, is essential 
for activation and intracellular transport of proteins crucial for various cellular functions, 
such as maintenance of cell shape, motility, factor secretion, differentiation, and 
proliferation.(Kuipers, Biesta et a l 2005) If HMG-CoA reductase is inhibited, there will be 
less mevalonate, less GGPP and less FPP and consequently less trans-cellular membrane 
transportation. It seems that statins have an effect on lipid raft-mediated intracellular 
transport and cell-surface expression of a variety of molecules or on the activation of certain 
proteins by isoprenylation, thereby affecting many cellular functions.
Previous work in the laboratory in Beaumont Hospital demonstrated a significant reduction in 
aortic root diameter and aortic root pathology in a murine model of Marfan syndrome with 
Pravastatin maintenance treatment.
4.2 Aims and objectives
The aim of this study was to determine if this observed attenuation of aortic pathology 
compared favourably with alternative pharmaceutical therapies which are cuiTently on trial in 
clinical studies.(Lacro, Dietz et a l 2007) The mechanism of action of each of the different 
therapies could be investigated at an ultra-structural level.
Our specific objectives were:
• To determine if Pravastatin therapy attenuated aortic root pathology measured by 
histological, echocardiographic and cardiovascular physiology parameters.
• To compare the effects of Pravastatin to both Losartan and Doxycycline.
• To determine if the mechanism of action was similar or different to Losartan and to 
Doxycycline.
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• To provide a basis for a further, more detailed study into the mechanisms of action of 
Pravastatin in the setting of Marfan syndrome.
4.3 Materials and Methods
A pair of male C1039G Marfan mice were cross bred with C57B16 females. Genetic analysis 
of the offspring was conducted. Male mice identified to have the C1039G mutation were 
entered into the study, as detailed in the materials and methods chapter. These mice were then 
entered into different treatment groups. Pharmacological agents were administered as 
outlined in Section 2.1.3.
The first group was administered Pravastatin from 6 weeks of age. The dose was 0.25g/Litre, 
equivalent to 50mg/kg/day. This dose was found in previous studies to reduce serum 
cholesterol levels in C57black6 mice (personal communication from Dr John Byrne).
The second group was administered Losartan from 6 weeks of age. The dose was 0.6g/Litre, 
which was the dose used in previous studies conducted in Johns Hopkins University. This 
dose was calculated by titrating the level of Losartan up, so that there was a 20mmHg 
reduction in the mean systolic blood pressure in the murine model.
The third group was administered Doxycycline from 6 weeks of age. The dose was 
0.24g/Litre, which is a sub-antimicrobial dose. This dose was used in previous studies and 
found to have a broad spectrum inhibitory effect on matrix metalloproteinases.
Each group were bom four weeks apart and investigations conducted three and eight months 
of age. The numbers in each group needed to be large enough to power the study adequately 
so the results would attain statistical significance. This meant that only one group of mice 
could be genotyped and tested from each month due to limited resources and capacity to 
breed and test a limited number of mice per month. Each group were subjected to the exact 
same conditions, and echocardiography conducted by the same ultra-sonographers at the
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same age relative to the other groups. Every effort was made to identify and reduce any 
variability that could arise between groups.
The drug treatment groups in the Marfan groups had an untreated Marfan group as a control 
and not all the drug treatment groups had a normal, wild-type, group which received 
treatment. It would be ideal, to have two type of control groups, one which has the disease 
without treatment and an internal control which does not have the disease, but received 
treatment. One control group was use due to limited resources.
These animals were then studied in the following manner;
Aortic root diameter was assessed in-vivo, at 3 months and 8 months for evidence of 
established and progression of aneurysmal dilatation, by trans-thoracic echocardiography as 
outlined in the materials and methods section.
Histology of aortic root pathology was assessed. Samples of aortic root were harvested at 8 
months. Aortic root thickness was assessed with Haematoxylin and Eosin staining. 
Architecture of the aortic media at the level of the aortic root was assessed by staining 
sections with Verhoeff van Gieson stain. The aortic wall architectural score is based on 
number of islands of damage (n=10 in each group) per full aortic root cross section. An island 
of damage is defined as an area where there are two or more disrupted elastic lamellae with 
associated thickening of the aortic media.
Cardiac function was assessed using haemodynamic variables from cardiac catheter 
recordings of dP/dt maximum and dP/dt minimum as measures of left ventricular systolic and 
diastolic function at 8 months.
Aortic valve function was assessed using catheter recordings of systolic and diastolic blood 
pressure. Assessment of the dicrotic notch was made by measuring dP/dt maximum of the
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downslope of the aortic trace (immediately after the peak systolic pressure and before the 
minimum diastolic value reached) at 8 months.
Samples of aortic root were harvested at 8 months for ultra-structural examination with 
electron microscopy. Measurements of aortic vascular smooth muscle cells were taken. The 
volume of rough endoplasmic reticulum was measured. The volume of the cistemae of the 
Golgi-apparatus was measured.
These results were compared to results of both untreated Marfan mice and normal mice from 
chapter 2, as positive and negative controls, respectively.
Echocardiograms were conducted on a Sequoia ultrasound machine.
This ultrasound machine, when used in M-mode displays a 2-dimensional image as 
demonstrated in figure 4.1 below.
In this figure we see an M-mode display of ultrasound image of aorta, at the level of the 
aortic root. This is also the level of the sinuses of Valsalva, which is the site of the origin of 
the coronary arteries. This image is obtained by first placing the probe over the sternum in 
long axis and locating the left ventricle and left ventricular outflow tract. The right 
ventricular outflow tract has a different course to the left as the right one passes into the main 
pulmonary artery, branches early at right angles to both the left and right pulmonary arteries, 
they are also deeper than the aorta. Once the left ventricular outflow tract has been localised, 
the image is switched to M-mode and the probe adjusted to a horizontal/cross-sectional 
position. In this view, the anterior and posterior aspect of the tract is imaged. As the walls of 
the ventricle contract and relax, due to systole and diastole as represented on M-mode, their 
tracing converge and diverge, i.e. the vertical distance between the anterior and posterior 
surfaces become shorter and longer respectively. The probe is moved very slightly cranially 
(towards the head). As the probe is moved, the image displays more distal left ventricular
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outflow tract, and the aortic valve leaflets may come into view. Once the anterior and 
posterior aspects of the wall stop converging and diverging, their traces start to move in 
parallel. This happens at the aortic annulus, where the aortic leaflets attach. Once above the 
aortic valve leaflets, an image of the tracing is saved, as shown in the figure below. The 
tracings of the anterior and posterior wall rise and fall. This represents the movement of the 
aorta due to systole and diastole. The tracing is closer to the probe in systole and further away 
(lower) in diastole. The tracings may still converge and diverge, but to a much lesser extent. 
This is due to the aortic pulse pressure. Three areas are agreed upon by the two veterinary 
radiologists reading the image, to be accurate representations of the aortic root. Three 
measurements are recorded in diastole.
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Figure 4.1: M-mode image of aortic root, with anterior and posterior aspects of aorta 
displayed by arrows in systole and anterior and posterior aspects of the aorta in 
diastole, labelled a, b, c & d respectively. The measurement of the aortic root diameter 
in diastole is also displayed, labelled e.
4.4 Results
All results reported will be followed in brackets by +/- estimated standard error of the mean, 
unless otherwise stated. Statistical analysis was conducted using an Analysis of Variance 
(ANOVA) with Bonferroni comparisons.
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The aortic root diameter enlarged from 0.16cm (+/-0.0019) in the normal group to 0.25cm 
(+/-0.0043) in the Marfan untreated group (results from chapter 3, figure 3.5 and figure 4.3). 
The aortic root diameter enlargement was attenuated significantly by Pravastatin treatment 
and reached 0.22cm(+/-0.005811) at eight months (p < 0.0001), in comparison to the Marfan 
untreated group (figure 4.2 and 4.3). The aortic root diameter enlargement was also 
attenuated significantly by Losartan treatment and reached 0.22cm (+/-0.005089) at eight 
months, (p < 0.0001) in comparison to the Marfan untreated group (figure 4.2 and 4.3). 
Doxycycline reduced the aortic root diameter to 0.24cm (+/- 0.005743) though did not 
achieve statistical significant difference (p= 0.09) in relation to the Marfan untreated group 
(figure 4.2 and 4.3).
4.4.1 Aortic root diameter results
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Mean Aortic Root Diameter comparing treatment groups to controls at 8 months
min - [mean ± 95% confidence in terval ] -m ax
Aortic root diameter (cm)
Figure 4.2: Mean aortic root diameter at 8 months comparing Marfan groups treated 
with pravastatin, losartan or doxycycline to untreated Marfan group and to a normal, 
untreated group. (P value labelled with * comparing normal, untreated group to 
Marfan untreated group. P value labelled with # comparing pravastatin or losartan or 
doxycycline treatment in Marfan groups to untreated Marfan group.)
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Comparison of Mean Aortic Root 
Diameter at 3 and 8 months between 
treatment and control groups
Aortic root diameter at 8 months 
Aortic root diameter at 3 months
Normal Marfan M arfan M arfan Marfan
Untreated Losart an Doxycycline Pravastatin
0.01
Standard deviation 
0.035 0.034 0.032 0.023
Control & Treatment groups
Figure 4.3: Aortic root diameter after 3 months (blue) and after 8 months (red) in 
centimeters. (Note: no scan conducted at 3 months in M arfan group treated with 
Pravastatin.) N= 118.
4.4.2 Cardiac Catheterisation Results
In chapter 2 it was found that there was no statistically significant difference in pulse pressure 
between the normal group, 40.7mmHg and the Marfan untreated group, 39.8mmHg(+/- 
1.302217), (figure 4.4). There was no statistical significant difference between the Marfan 
group treated with high dose Pravastatin, mean = 36.5mmHg (+/-1.448542) and the untreated 
Marfan group, mean = 39.8mmHg (+/-1.302217), (p = 0.3722) as shown in figure 4.4. The
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Losarían treated Marfan group did have a narrower pulse pressure on invasive measuring of 
the aortic pulse pressure. The pulse pressure reduced to 32.1 mmHg (+/-1.397952), (p < 
0.0001), figure 4.4.
Comparison of Mean Aortic Pulse Pressure between 
treatment groups and controls
Aortic Pulse Pressure (mmHg)
Figure 4.4: Comparison of Mean Aortic Pulse Pressure between Marfan groups treated 
with losartan or pravastatin versus Marfan untreated group and normal group. N = 
100. ( p-values refer to comparison with normal untreated group labelled *)
4.4.3 Histology Results
As in chapter 2, three aspects of histology were assessed: aortic wall thickness, architectural 
score and the amount of elastin within the media of the aortic wall.
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Aortic wall thickness (micrometers)
Treatment &
control
rrin -[ wean ± 95% confidence interval ]-max
Mean Aortic wall thickness (pm)
Figure 4.5: Chart of aortic wall thickness (Mm), comparing normal, M arfan, and 
M arfan treated with pravastatin, losartan and doxycycline. N = 50.
The mean aortic wall thickness of the Marfan untreated group was 151.68micrometers (+/- 
12.791671), which was significantly different to the mean aortic wall thickness of the 
normal group which was 104.8 micrometers, (p=0.0009), (figure 4.5). The mean aortic wall 
thickness of the Pravastatin group was 166.49 micrometers (+/-13.567616), (figure 4.5). 
There was no statistical difference between the Marfan treated with Pravastatin group and 
the Marfan untreated group, 151.68 micrometers (+/-12.791671), (p = 0.34), (figure 4.5).
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There was a significant reduction in the thickness of the aortic wall in the Losartan group,
111.92 micrometers (+/-13.142192), with respect to the untreated Marfan group (p = 
0.0048), (figure 4.5). Doxycycline showed a significant increase in the aortic wall thickness 
with respect to the untreated Marfan group (p = 0.0099) with the thickness increasing to
191.93 micrometers (+/-14.87921), (figure 4.5).
Comparison of architectural score of the
nin ■{mean ± 95% confidence interval}- max
Architectural score of the aortic medial
Figure 4.6: Architectural score of the aortic medial layer, a comparison of treatment 
groups in Marfan syndrome; pravastatin; losartan; doxycycline and normal and 
Marfan control groups. N = 50.
The architectural score was calculated as describe above in the materials and methods 
section. In the Marfan untreated group, the architectural score of the aortic media was 
significantly increased from 0.6 (+/-0.163299) in the normal group to 13.076923 (+/- 
2.555691) in the Marfan group (p = 0.0106), (figure 4.6). The aortic wall architectural score 
was not significantly different in the Marfan group treated with Pravastatin, 21.1 (+/-
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2.814447) when compared to untreated the Marfan group, (p = 0.0936), (figure 4.6). Losartan 
improved the aortic wall architectural score at 10.25 (+/-4.241588), which remained 
statistically significant in comparison to the Marfan untreated group (p = 0.5752), (figure
4.6). Doxycycline had a statistically significant negative effect on the aortic wall architecture, 
measured at 22.7273 (+/-4.566585), with respect to the Marfan untreated group (p = 0.0399), 
(figure 4.6).
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Comparison of the mean elastin volume as a proportion of the 
tunica media of the aortic wall, at the level o f the aortic root
rrin - [mean ± standatd deviation ]- max
Vv Elastin : Media (mean elastin volume as a 
proportion of the tunica media of the aortic wall, 
at the level of the aortic root)
Figure 4.7: Elastin volume as a proportion of the tunica media of the aortic wall, at the 
level of the aortic root, a comparison of treatment groups in Marfan syndrome; 
pravastatin; losartan; doxycycline and normal and Marfan control groups (n = 25).
In the Marfan untreated group, the volume of elastin within the aortic media of the aortic 
wall, as a proportion of the volume of the media, was reduced significantly from 0.27(+/- 
0.019847) in the normal group to 0.18(+/-0.018801) in the Marfan group (p = 0.0144), (figure
4.7). Pravastatin rescued the destruction of elastin within the media significantly, with an 
increased proportional volume of elastin: media, 0.2275(+/-0.020858) (p = 0.0136), (figure
4.7). Losartan improved the volume of elastin: media further still, and the level rose to above 
that of normal, 0.29(+/-0.029886), which remained statistically significant in comparison to
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the Marfan untreated group (p = 0.0037), (figure 4.7). Doxycycline did not improve the 
volume of elastin significantly, 0.19625(+/-0.027856), with respect to the Marfan untreated 
group (p = 0.7463), (figure 4.7).
4.4.4 Electron Microscopy / Ultra-structural analysis
Treatment Volume of rough Endoplasmic Reticulum : Cytoplasm
& control
win - [ low er quartile - median - upperquartile }- max
Volume of rough Endoplasmic Reticulum as 
a proportion of the volume of Cytoplasm
Figure 4.8: Comparison of volume of rough endoplasmic reticulum: Cytoplasm between 
treatment and control groups.
As observed in chapter one the volume of rough Endoplasmic Reticulum as a proportion of 
the aortic smooth muscle cell, was increased from 0.00914(+/-0.001056) in normal aortic 
smooth muscle cells, compared to Marfan aortic smooth muscle cell 0.03461 (+/0.004413), 
with p = 0.0001, (figure 4.8). Pravastatin reduced the proportion of rough Endoplasmic 
Reticulum in the Marfan aortic smooth muscle cell to 0.0217(+/-0.004386), with p = 0.0083, 
(figure 4.8). Losartan reduced the proportion of rough Endoplasmic Reticulum to 0.01289(+/- 
0.000912), with p < 0.0001, when compared to the Marfan untreated group (figure 4.8).
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Losartan reduced the RER level close to that of normal, so much so that there is no statistical
variance with Bonferroni comparisons is conducted. Doxycycline reduced the proportion of 
rough Endoplasmic Reticulum to 0.023073 (+/-0.002831) (p = 0.0166) when compared to the 
Marfan untreated group (figure 4.8).
4.4.5 Electron photomicrographs of aortic tissue from different treatment and control 
groups.
Note is made of the smooth undulating, wave like pattern of the el as tin fibres which provide 
the strength and compliance of normal aortic tissue (Figure 3.16, in chapter 3). In Figure 3.19 
(in chapter 3), the smooth undulating, wave like pattern of the elastin fibres was disrupted 
and fragmented, as shown by blue arrows. Thus, the strength and compliance of the aortic 
tissue was compromised. Figures 4.9 -  4.12 represent samples of aortic tissue taken from the 
Marfan group treated with Pravastatin. There are some breaks in the continuity of the elastic 
lamellae with a less organised pattern of vascular smooth muscle than compared to normal 
tissue. In figure 4.12 ultra-stuctural elements of the aortic vascular smooth muscle are 
observed, including the structure of the nucleus and the cell’s own transportation system, the 
rough endoplasmic reticulum.
difference between normal and Marfan treated with Losartan (p = 0.40) when an analysis of
aortic root tissue, with pravastatin
treatment. Scale bar: 10pm.
citrate stained resin section of Marfan
Figure 4.9 Transmission electron
micrograph of a uranyl acetate and lead
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Figure 4.10 Marfan murine aortic root in pravastatin treated group. Scale bar: 10pm. 
Transmission electron micrograph of a uranyl acetate and lead citrate stained resin 
section of elastic lamellae (white arrows) and SMCs (black arrows) within the aortic 
media.
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Figure 4.11 Pravastatin treated Marfan murine aortic root. Scale bar: 2pm. 
Transmission electron micrograph of a uranyl acetate and lead citrate stained resin 
section of a SMC (white arrow) lying between two elastic lamellae (white asterisks).
Figure 4.12 Pravastatin treated Marfan murine aortic root. Scale bar: 500nm.
Transmission electron micrograph of a uranyl acetate and lead citrate stained resin
section of a SMC nucleus (white asterisk) surrounded by RER (white arrow).
Figure 4.13 Scale bar: 500nm.
Transmission electron micrograph of a 
uranyl acetate and lead citrate stained
resin section of Losartan treated
Marfan murine aortic root.
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Figure 4.14 Losartan-treated group, Marfan, murine aortic root. Scale bar: 10pm 
Transmission electron micrograph of a uranyl acetate and lead citrate stained resin 
section of the concentric bands of elastic lamellae (white asterisks) interspersed with 
SMCs (white arrows) within the tunica media.
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Figure 4.15 Losartan treated Marfan murine aortic root. Scale bar: 2pm. 
Transmission electron micrograph of a uranyl acetate and lead citrate stained resin 
section of a SMC (black arrow) lying between two elastic lamellae (white asterisks).
Figures 4.13-4.16 show electron photomicrographs of Marfan (murine) aortic root treated 
with Losartan. Continuity and thickness of the elastic lamellae appear preserved with an 
arranged pattern of vascular smooth muscle cells in between these layers. Ultra-structural 
components of the aortic vascular smooth muscle cells, including the nucleus and rough 
endoplasmic reticulum, are observed (Figure 4.16).
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Figure 4.16 Losartan-treated Marfan murine aortic root. Scale bar: 500nm. 
Transmission electron micrograph of a uranyl acetate and lead citrate stained resin 
section of a SMC nucleus (white asterisk) surrounded by RER (white arrow).
Figure 4.17 Doxycy cline treated
Marfan murine aortic root. Scale bar: 
10pm. Transmission electron 
micrograph of a uranyl acetate and lead 
citrate stained resin section.
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Figure 4.18 Doxycycline treated Marfan murine aortic root. Scale bar: 10pm. 
Transmission electron micrograph of a uranyl acetate and lead citrate stained resin 
section of a broken elastic lamella (white asterisk) and SMC (white arrow) within the 
tunica media.
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Figure 4.19 Doxycycline treated Marfan murine aortic root. Scale bar: 500nm. 
Transmission electron micrograph of a uranyl acetate and lead citrate stained resin 
section of a SMC nucleus (black asterisk) surrounded by RER (black arrow) within the 
tunica media.
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Figure 4.20 Doxycycline treated Marfan murine aortic root. Scale bar: 500nm. 
Transmission electron micrograph of a uranyl acetate and lead citrate stained resin 
section of a SMC nucleus (black asterisk) surrounded by RER (black arrow) and a 
Golgi complex (white arrow).
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Figure 4.21 Marfan aortic root, doxycycline treatment group, with magnification of 
aortic vascular smooth muscle. The Golgi apparatus is displayed with a yellow ellipse.
Electron photomicrographs of murine aortic root tissue from the Marfan group with 
Doxycycline treatment are shown in figures 4.17-4.21. Gross disruption and thinning of the 
elastic lamellae with interposition of the aortic vascular smooth muscle cells are present 
(Figures 4.17 and 4.18). Ultra-structural differences are observed in the aortic vascular 
smooth muscle cells with Doxycycline treatment (Figures 4.19 - 4.21), which are similar to 
that of untreated Marfan aortic vascular smooth muscle cells.
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4.5 Discussion
Pravastatin had a beneficial effect by attenuating dilatation of the aortic root diameter by 
33.3% in a group of Marfan mice treated with Pravastatin as compared to the group of 
Marfan mice with no treatment. This was a statistically significant finding. It may also be 
relevant clinically, as a one third reduction in growth rate is a very significant finding. In the 
era before open heart surgery, the life expectancy for a person with Marfan syndrome was 45 
years of age, due to the risk of aortic dissection, secondary to aortic aneurysmal 
disease.(Murdoch, Walker et al. 1972) In clinical practice growth rates are monitored initially 
with 6 monthly measurement of the thoracic aorta, then annually once stability is 
established.(Milewicz, Dietz et a l 2005; Hiratzka, Bakris et al 2010) Surgical repair is 
indicated in Marfan syndrome if the aortic root or ascending thoracic aorta reaches a 
threshold of 5.0cm or rapid enlargement, 0.5cm per year.(Elefteriades 2002) Studies have 
shown that beta blockade helps to slow dilatation of the aorta, though in patients with Marfan 
syndrome, the aorta continues to dilate and dissect despite medical therapy, so beta-blockade 
does not preclude the need for routine imaging and prophylactic aortic repair when the 
diameter of the aorta warrants repair. (Shores, Berger et a l 1994) These facts mean that a 
33.3% reduction in growth rate, found in a murine model, could have a significant clinical 
impact. Pravastatin also improved elastin volume, though showed no benefit in aberrant 
aortic wall thickening or architectural disruption. Improvement in elastin volume related to 
Pravastatin therapy in a murine model of Marfan syndrome is also a novel finding, as elastin 
content is reduced in Marfan syndrome, (Abraham, Perejda et a l 1982) and marked 
disruption of elastin is evident in untreated groups within this and other studies. (Habashi, 
Judge et a l 2006)
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Losarían also had a beneficial effect by attenuating dilatation of the aortic root diameter by 
33.3% in a group of Marfan mice treated with Losartan as compared to the group of Marfan 
mice with no treatment. This is a statistically significant result, which may be clinically 
relevant due to its magnitude. This result is similar to previous studies with Losartan in 
murine models of Marfan syndrome.(Habashi, Judge et a l 2006) The aberrant aortic wall 
thickening in the Marfan untreated group was brought to near normal levels with Losartan, 
which is similar to studies conducted in Johns Hopkins.(Habashi, Judge et a l 2006) Elastin 
volume was preserved in the Losartan treatment group. Unfortunately, Losartan did not 
improve the amount of architectural disruption within the aortic medial layer. Clinical trials 
with Losartan treatment for aortic aneurysmal disease have commenced in patients with 
Marfan syndrome.(Lacro, Dietz et a l 2007; Radonic, de Witte et a l 2010; Forteza, 
Evangelista et a l 2011)
Pulse pressure was measured and found to be lower in the Marfan group which received 
Losartan treatment. This would reflect Losartan5s blood pressure lowering property rather 
than an effect on the competency of the aortic valve. This anti-hypertensive effect possibly 
reduces the strain on the aorta itself, which could be an additional part of Losartan’s 
beneficial effect. The dP/dt max was measured between the groups and the contractility index 
(dP/dt max divided by the left ventricular end diastolic pressure). Measurements of the 
contractility index showed no statistical difference between treatment groups.
Doxycycline did not improve aortic root dilatation. It had overall higher 3 month and 8 month 
aortic root measurements. A significant increase was observed in the aortic wall thickness in 
the Marfan groups treated with Doxycycline. Architectural disruption was increased with no 
change in elastin volume when compared to untreated Marfan mice.
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The ranges of values for the size of the aortic root diameter, was wider in the treatment and 
Marfan groups, than that of the normal, no treatment group. This reflects a phenomenon of 
aneurysmal disease, that once an aortic root becomes aneurysmal, the diameter is enlarging 
and so becomes more variable in the diseased state. The rate of enlargement of an aortic 
aneurysm is more rapid in Marfan syndrome and so, more difficult to predict. (Davies, 
Goldstein et a l 2002)
TGF-P signalling appears critical to the pathogenesis in Marfan syndrome. Excessive 
unsequestered TGF-P is present in the extracellular matrix. This active TGF-p binds to the 
TGF-p receptor, which is involved with phosphorylation of Smad proteins. Once 
phosphorylated, they start a cascade which sends a signal to the nucleus to start transcribing 
messenger RNA which in turn is transported to the rough endoplasmic reticulum, which is 
located around the nucleus. The rough endoplasmic reticulum synthesizes proteins. Specific 
messenger RNA transcribed by the nucleus in this situation stimulates production of proteins 
involved in homeostasis of the extracellular matrix, such as matrix metalloproteinases and 
proteoglycans. The surface of the rough endoplasmic reticulum has many ribosomes attached. 
These ribosomes are involved in protein manufacturing. They give the endoplasmic reticulum 
the “rough” appearance. A  ribosome binds to the rough endoplasmic reticulum once it begins 
to synthesize a protein that is destined for the secretory pathway. These proteins are then 
shuttled within membrane-bound vesicles to the Golgi apparatus, destined for secretion 
outside the cell. For this to occur, they first require localisation to the cellular membrane. 
Localisation is facilitated by a post-translational modification of the protein with a lipophilic 
group. Isoprenoid pyrophosphates serve as this essential lipophilic group which aids 
anchoring of the protein to the phospholipid bilayer. Anchoring facilitates interaction with the 
cell membrane and so transportation across the cell membrane.
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Increased levels of unsequestered TGF-p, secondary to fibrillin-1 deficiency in Marfan 
syndrome, upregulate pSmad signalling, and thus increase the amount of protein production. 
The excessive level of protein production within the vascular smooth muscle cells is visible at 
an ultra-structural level as an increased amount of rough endoplasmic reticulum, which is 
where the proteins are being produced and transported out of the cell. The Marfan group 
which was treated with Losartan showed similar volumes of rough endoplasmic reticulum to 
the normal group. This reflected normalisation of the levels of protein production in the 
Marfan group treated with Losartan. This was previously noted to be related to the TGF-P 
receptor antagonism effect of Losartan. Excessive protein production is being inhibited “up­
stream”, blocking TGF-p signalling at the level of the cell membrane receptor and so up- 
regulation of protein production is halted before it even begins. This causes a marked 
reduction in the rough endoplasmic reticulum volume within the vascular smooth muscle cell. 
Statins on the other hand seem to cause a modest but not as marked reduction in RER 
volume. This suggests that some abnormal protein production is still occurring in the statin 
(Pravastatin) group, so the statins modest but not complete reduction in RER volume is likely 
a post-translational protein effect. This post-translational effect could be related to a 
reduction in the levels of isoprenyl groups available for prenylation of proteins. This would 
be secondary to inhibition of production of mevalonate by Pravastatin which is a H M G  Co-A 
reductase inhibitor.
In this study Losartan was better than Pravastatin, and Doxycycline has no effect.
Chung et a l, found that Doxycycline was more effective than atenolol at preventing thoracic 
aortic aneurysm in murine model of Marfan syndrome, with preservation of aortic wall elastic 
fibres and normalisation of aortic wall architecture.(Chung, Yang et a l 2008) Aortic root 
diameter, at 9 months was reduced from 2.31+/-0.13mm in the untreated Marfan group 
versus 1.78+/-0.04mm in the Marfan group treated with Doxycycline (0.24g/L) from 6 weeks
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of age. They proposed that this protective effect was due to inhibition of matrix 
metalloproteinase 2 &  9, and a reduction of TGF-p. This was in contrast to the results 
outlined in this chapter. This study showed an increased level of architectural disruption and 
a decrease in elastic fibre volume with Doxycycline treatment. A potential cause for a 
difference between this study and the results from Chung et al., is that n = 30 in the treatment 
group, 10 euthanized at 3, 6 and 9 month. Our results had a larger number, n = 17, of aortic 
specimens assessed at 8 months, and this assessment focused on the aortic root. Chung et 
al averaged there results from different sections of the aorta, which could have an effect of 
falsely normalising measurements of the aorta. Our results show a wider variability, despite a 
higher number of specimens, which might suggest a higher degree of variability of response 
to Doxycycline treatment. Descending thoracic aortas are relatively spared from disease in 
this particular murine model of disease. There may have been, an unexpected variability 
introduced into each of the two conflicting studies.
Habashi et a l, found Losartan prevented aortic aneurysm in a murine model of Marfan 
syndrome (Habashi, Judge et a l 2006). The Marfan group treated with Losartan showed 
improvement in aortic root elastic fibre architecture, aortic wall medial thickness and aortic 
root diameter (growth rate and absolute diameter) compared to placebo treated Marfan groups 
and showed full normalisation compared to wild-type mice. Other studies have shown that 
Losartan reduces the expression of matrix metalloproteinases 2 and 9,(Yang, Kim et a l 2009) 
and are related to TBG-p expression.(Matt, Habashi et a l 2008) The initial studies conducted 
by Habashi et.al (Habashi, Judge et al 2006) are similar to our study which shows an 
improvement in aortic root diameter, aortic wall thickness, though aortic wall architecture 
was not improved in our study. We also found that the volume of elastic fibres within the 
aortic root media was preserved with Losartan.
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In summary, Losarían is very effective at reducing the aortic root diameter. It also normalises 
aortic wall thickness and preserved elastic fibre content. It did not preserve aortic wall 
architecture in our study, although it has been shown in another study to have a positive 
effect on this parameter.(Habashi, Judge et a l 2006) The beneficial effect has previously 
been noted to be attributed to TGF-p receptor antagonism, with a consequential reduction in 
excessive protein production.(Habashi, Judge et a l 2006; Matt, Habashi et a l 2008) 
Normalisation of protein production was suggested by a reduced amount of cell organelles 
involved in this function by observations at an ultra-structural level within the vascular 
smooth muscle cells of the aortic root in Marfan syndrome in the Pravastatin &  Losartan 
treatment groups. Pravastatin treatment compared favourably to Losartan. In fact, Pravastatin 
is equipotent to Losartan in attenuating absolute aortic root diameter in Marfan syndrome. It 
also had a beneficial effect on preserving aortic elastic fibre content, though did not reduce 
aortic wall thickening or aortic wall architecture. The beneficial effect of Pravastatin may be 
related to reducing the cell’s ability to process the excessive amount of protein that arises 
within the vascular smooth muscle cell in Marfan syndrome. Doxycycline was inferior to 
both Pravastatin and Losartan. Doxycycline and Losartan have been studied as a combined 
treatment with beneficial effects on the structure of the aortic wall.(Yang, Kim et a l 2010) 
The results of ultra-structural analysis in this study suggest that Losartan and Pravastatin have 
different mechanisms of action. This would open up the possibility that if given together for 
treatment of aortic root pathology in Marfan syndrome, they may have a combined, 
synergistic effect more potent than if given alone.
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Pravastatin attenuates aortic root pathology, optimisation of dose and timing of therapy 
in Marfan syndrome
5.1 Introduction:
Having demonstrated an improvement in aortic root diameter in Marfan syndrome with a 
novel pharmaceutical therapy, Pravastatin, the hypothesis was that this improvement could be 
further increased if the dose was increased by a factor of two. This would mean the dose of 
Pravastatin would increase from 50mg/kg to lOOmg/kg. Higher doses of Pravastatin tended 
towards a more significant beneficial effect on cholesterol lowering.(Byrne 2008) Increasing 
the dose of Pravastatin has been shown to decrease serum lipid levels. (Hunninghake, Knopp 
et a l 1990) The dose of Pravastatin was titrated up until serum cholesterol levels decreased. 
Pravastatin has been shown to have dose dependent effects on inflammatory response, 
independent of lipid lowering effects, in patients suffering from myocardial infarction.(Di 
Garbo, Bono et al. 2000)
The treatment of Marfan syndrome would be a novel indication for this drug which is 
already established as a treatment for hypercholesterolaemia(Jones, Farmer et a l 1991) and 
secondary prevention for atherosclerotic related disease such as ischemic heart 
disease(Glasziou, Eckermann et a l 2002) and cerebrovascular disease.(Koizumi, Shimizu et 
a l 2002) Pravastatin therapy was shown by Dr. John Byrne &  Dr. Jonathan McGuinness to 
attenuate aortic pathology, when therapy was commenced at 6 weeks of age in a murine 
model.
There are over 400 sporadic mutations of the fibrillin-1 gene that cause Marfan syndrome. It 
may be possible to screen offspring of known patients, who have known mutation but, it is 
not feasible to screen the population for all of the known mutations at birth, or in early
Chapter 5
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childhood. The diagnosis is essentially clinical. In 1995, a group of the world's leading 
clinicians and investigators in Marfan syndrome proposed revised diagnostic criteria. Known 
as the Ghent criteria, they identify major and minor diagnostic findings, which are largely 
based on clinical observation of various organ systems and on the family history. This has 
since been updated.(Loeys, Dietz et a l 2010) A major criterion is defined as one that carries 
high diagnostic precision because it is relatively infrequent in other conditions and in the 
general population. The Ghent criteria were intended to serve as an international standard for 
clinical and molecular studies and for investigations of genetic heterogeneity and genotype- 
phenotype correlations. The clinical diagnosis in adults should be made using the revised 
Ghent criteria, which are unreliable in children. Most clinical features are specific to age, and 
some features may not manifest until relatively late in life. This feature may make diagnosis 
in childhood difficult. Aortic root dilatation involving the sinuses of Valsalva in Marfan 
syndrome occurs in 70-80% of patients.(Hwa, Richards et a l 1993) It manifests at an early 
age and tends to be more common in men than women.
With these facts in mind, the second hypothesis was that the treatment could become more 
clinically relevant if the treatment benefit was preserved despite commencing therapy at a 
later stage. This may evaluate the relevance and speed up translation into clinical practice. 
Statin therapy may have an effect on the normal aorta. (Steinmetz, Buckley et a l 2005) The 
effect may, be unrelated to its effects in Marfan syndrome. To investigate the extent of effect 
Pravastatin has on the Marfan disease process specifically, a group of normal, wild-type mice 
were administered Pravastatin.
The specific objectives of this study therefore were as follows:
• To determine if the observed beneficial effect of Pravastatin therapy was preserved 
with commencement of treatment at a later stage in the disease process.
• To determine if an increased dose would confer an increased benefit.
144
• To determine the effect o f  Pravastatin therapy has on normal aorta.
5.2 Materials and Methods:
A pair of male C1039G Marfan mice was cross bred with C57B16 females. Genetic analysis 
of the offspring was conducted. Male mice identified to have the C1039G mutation were 
entered into the study, as detailed in the materials and methods section.
These mice were then entered into four different treatment groups.
The first group was administered Pravastatin from 6 weeks of age. The dose was 0.25g/Litre, 
equivalent to 50mg/kg/day.
The second group was administered Pravastatin from 4 months of age. The dose administered 
was 50mg/kg/day.
The third group was administered Pravastatin from 5 months of age. The dose administered 
was 50mg/kg/day.
The fourth group was administered Pravastatin from 6 weeks of age. The dose administered 
was 100mg/kg/day.
The fifth group contained wild-type mice and was administered Pravastatin from 6 weeks of 
age. The dose administered was 50mg/kg/day.
The results from untreated Marfan group and untreated wild-type group from the comparison 
chapter 3 were used as positive and negative controls. Drug administration was conducted as 
per methods outlined in chapter 2, section 2.1.2.
These animals were then studied in the following manner;
Aortic root diameter was assessed in-vivo, at 3 months and 8 months for evidence of 
progression of aneurysmal dilatation, by trans-thoracic echocardiography as outlined in the 
materials and methods in chapter 2 section 2.1.4.
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Histology of aortic root pathology was assessed as per methods outlined in chapter 2, section 
2.6. Samples of aortic root were harvested at 8 months. Aortic root thickness was assessed 
with Haematoxylin and Eosin staining. Architecture of the aortic media at the level of the 
aortic root was assessed by staining sections with Verhoeff van Gieson stain. The amount of 
proteoglycan (within the connective tissue matrix) staining within the aortic media was 
assessed by histological cross-sections of the aortic root with Alcian blue stain. The intensity 
of staining was assigned a grade of 1, 2, 3 or 4, with increasing intensity of stain deposition 
within the aortic media.
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Results when given are immediately followed by +/- standard error of the mean in brackets.
5.3.1 The effect of pravastatin on the normal aorta
5.3 Results
Aortic Root Diameter at 3 & 8 months
p=0.0006 p=0.0047
■ 3 months
■ 8 months
Normal-untreated Normal-Pravastatin
Figure 5.1: Mean aortic root diameter (cm), normal versus normal treated with 
pravastatin at 3 &  8 months.
The mean aortic root diameter was reduced in the normal group treated with Pravastatin at 8 
months compared to normal mice who were not given Pravastatin at 8 months. The mean 
aortic root diameter wsa reduced from 0.161cm (+/-0.001) in normal, mice to 0.155cm (+/- 
0.002)in Pravastatin treated mice, which was statistically significant (p=0.0047).
147
Aortic wall thickness
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Figure 5.2: Aortic wall thickness (|Jm) in normal & normal treated with pravastatin 
groups at 8 months, showing the spread of values & interquartile range« The two groups 
are similar.
The mean aortic wall thickness was similar in both the normal group, 104.8pm(+/-6.5) and in 
the normal treated with Pravastatin group, 106.4pm(+/-4.4). The aortic specimens were taken 
from 10 different mice from each group.
The mean aortic wall architectural score was similar in both the normal group, 0.6(+/-0.16), 
and in the normal treated with Pravastatin group, l.l(+/-0.55).
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Aortic Wall Architectural Score at 8 m onths
rrin i  low e r quartile - median - upper quattile ]-  max
Aortic wall architectural score
Figure 5.3: The mean aortic wall architectural score in both normal & normal treated 
with pravastatin.
The range of the mean aortic wall architectural score shows a wider range in the normal 
Pravastatin treated group, though there is no statistical difference between the groups.
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5.3.2 Optimising the dose of pravastatin for aortic pathology in Marfan syndrome
Aortic root diameter at 
8 months
0.26
_  0.25
» 0.24
S3 0.23
Aortic root diameter (cm)
0.22
0.21
Marian-untreated Marfan-Pravastatin 100
Marfan-Pravastatin 50
Figure 5.4: Aortic root diameter at 8 months (cm), Pravastatin Dose 50 mg/kg versus 
100 mg/kg in Marfan treated versus Marfan untreated. Dosing began at 6 weeks. The 
figure shows a reduction in aortic root diameter in a dose dependent fashion (n =75). 
Statistics to accompany figure, in Table 5.1 below.
Marfan Groups Untreated Pravastatin 50 Pravastatin 100
Standard
deviation
0.035 0.035 0.023
p value 0.0004
[compared to 
untreated]
<0.0001
[compared to 
untreated]
Table 5.1: Table to accompany Figure 5.4 Aortic root diameter at 8 months (cm),
Pravastatin Dose 50 mg/kg versus 100 mg/kg in Marfan treated versus Marfan
150
untreated. The table shows a both standard deviations and p-values for the marfan 
groups derived by analysis of variance with Bonferroni correction.
When Pravastatin therapy was initiated at 6 weeks of age at a dose of 50mg/kg the aortic root 
diameter at 8 months was reduced from 0.252 cm, to 0.233cm. There was a further reduction 
in the mean aortic root diameter at 8 months, 0.22cm, when a higher dose of lOOmg/kg was 
administered from 6 weeks of age.
Aortic wall thickness, Pravastatin dose variation
Marfan P 100
Marfan P50
Marfan untreated
50
i ’  1 1
100
I ------1------ r
150 200
#P=0.3175
*P=0.3759
*#
250
min -{ mean ± standard deviation }- max
Aortic wall thickness (urn)
Figure 5.5: Aortic wall thickness (fJm), Marfan untreated versus Pravastatin Dose 50 
mg/kg versus 100 mg/kg in Marfan groups. Dosing began at 6 weeks. The mean, 
maximum & minimum values with one standard deviation are displayed. The means 
are similar, though the range and standard deviation is wider in the Marfan group 
treated with pravastatin lOOmg/kg.
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Aortic wall architecture, pravastatin dose variation
Aortic wall architectural score
Figure 5.6: Aortic wall architecture, Marfan untreated versus pravastatin dosed 
Marfan at 50 mg/kg(pravastation 50) versus 100 mg/kg(High dose pravastatin). Dosing 
of these groups began at 6 weeks. The mean, maximum & minimum values with one 
standard deviation are displayed. The means vary, and both the treatment groups have 
higher values than the untreated Marfan group, though not in a dose dependent 
fashion.
Aortic wall architecture was assessed in three Marfan groups. The first group was untreated 
(n=13), the second and third were administered Pravastatin from 6 weeks of age at a dose of 
50mg/kg (n-10) and lOOmg/kg (n=10). The mean aortic wall architecture score was 13 for 
the untreated Marfan group, 30.8 for the 50mg/kg Pravastatin group (p=0.0074) and 21.1 for 
the lOOmg/kg group (p=0.20).
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The mean, maximum &  minimum values with one standard deviation are displayed. The 
means vary, and both the treatment groups have higher values than the untreated Marfan 
group, though not in a dose dependent fashion.
5.3.3 Investigation of the optimum timing of initiation of pravastatin therapy for 
aortic pathology in Marfan syndrome
Aortic root diameter (cm) in Marfan groups treated with 
50mg/kg of Pravastatin. Comparing initiation time-points
trin  - { low e r quartiie - median - upper quartile ] -  max
Aortic root diameter (cm)
*P=0.59
*P=0.29
#P<0.001
Figure 5.7: Aortic root diameter (cm), at 8 months of age, in Marfan groups treated 
with 50mg/kg of pravastatin & control untreated Marfan group. Comparing effect of 
varying age at which treatment was initiated.
Aortic root diameters were observed to be similar in both late start groups to the normal start 
group at a dose of 50mg/kg.
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Different therapy initiation time-points, 
aortic wall thickness (|Jm)
200 p=0.57 p=0.42 p=0.14
Untreated normal start late start very late start
Figure 5.8: Aortic wall thickness (fim), at 8 months of age, in Marfan groups treated 
with 50mg/kg of pravastatin. Compared effect of varying age at which treatment was 
initiated, with a control, untreated marfan group. [Normal start refers to treatment 
initiation at 6 weeks of age. Late start refers to treatment initiation at 4 months of age. 
Very late start refers to treatment initiation at 5 months of age.]
Mean aberrant aortic wall thickening varied, though the variation did not reach statistical 
significance.
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Aortic wall architecture, Therapy in itia tion  tim e-points
Figure 5.9: Aortic architectural score, at 8 months of age, in Marfan groups treated 
with 50mg/kg of pravastatin. Compared effect of varying age at which treatment was 
initiated, with a control, untreated Marfan group. [Normal start refers to treatment 
initiation at 6 weeks of age. Late start refers to treatment initiation at 4 months of age. 
Very late start refers to treatment initiation at 5 months of age.]
Aortic architectural disruption showed no statistical-significant difference in the Marfan 
groups in which Pravastatin was commenced at different time-points.
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5.3.4 Effect of pravastatin on proteoglycan deposition within the aortic wall.
Figure 5.10: Histological images, cross-sections of normal aorta stained with Alcian 
Blue. This is the normal intensity of staining of the aorta wall, forming a baseline for 
assessing proteoglycan deposition within the aortic wall.
Figure 5.11: Histological images, cross-sections of aorta stained with Alcian Blue from 
the Marfan group that has received no treatment. There is intense staining of the aorta 
wall, indicating a significant increase in the amount of proteoglycan deposition within 
the media.
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Figure 5.12: Histological images, cross-sections of aorta stained with Alcian Blue from 
the Marfan group that has received pravastatin (50mg/kg) treatment from six weeks of 
age. There is less intense staining of the aorta wall, indicating less proteoglycan 
deposition.
Histological cross-sections of aortic root were stained with Alcian Blue to assess glycogen 
deposition within the aortic media. Figure 5.10 above displays a baseline staining intensity 
for normal aorta. Comparing this to the Marfan untreated aortic wall, there is a dramatic 
increase in the intensity of Alcian Blue staining. This reflects an increase in the amount of 
glycogen deposition within the aortic media in Marfan syndrome. The intensity of Alcian 
Blue staining is greatly reduced in the Marfan group treated with Pravastatin (50mg/kg). The 
reduction in the intensity of staining reflected a reduced level of proteoglycan deposition 
within the aortic wall in the Pravastatin treatment group. This is qualitative data, following 
assessment of samples from at least 10 different specimens from each group.
157
Alcian blue - grade of stainin gbetween normal, marfan & marfan treated with pra'
Grade of staining
Figure 5.13: Alcian blue grade of staining in Normal, Marfan & Marfan treated with 
pravastatin groups.
5.4 Discussion
Aortic root growth rate was observed in normal, untreated mice and normal mice treated with 
Pravastatin. There was a significant difference in growth rate between the two groups. The 
treatment group had a growth rate 53% that of the untreated group. The overall aortic root 
diameter at 8 months showed a difference of a 3.7% reduction in the treatment group, which 
was statistically significant. In human studies the effect of statin treatment on normal aortic 
wall remains to be elucidated.(Muehling, Oberhuber et al. 2008) There was no difference in 
the thickness of the aortic wall between the groups. Nor was there a significant difference 
between the aortic architectural score between the two groups. This information would have 
implications for treating any patient with Pravastatin for aortic aneurysmal disease. It is 
important to know that Pravastatin reduces dilatation of the aortic root in the normal aorta,
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without an increase in thickness, nor disruption of the architecture of the wall. Pravastatin 
does not have deleterious effects on the structure of the aortic root. Pravastatin treatment has 
many beneficial effects for patients with cardiovascular disease (Shepherd, Cobbe et a l 
1995), though rates of statin use in an older female population is only 22%.(Lawlor, Bedford 
et a l 2003) Statins have been shown to reduce the proteolytic activity within the wall of 
aortic aneurysms of the abdominal aortic wall.(Abisi, Bumand et a l 2008) Preoperative statin 
therapy was associated with improved outcomes in patient who were undergoing abdominal 
aortic aneurysm repair.(McNally, Agle et a l 2010) Recent guidelines recommend that for 
patients who have thoracic aortic aneurysmal disease, dyslipidaemia should be treated, with 
statin therapy, for patients with non-coronary atherosclerotic disease, atherosclerotic aortic 
aneurysm, and co-existing coronary heart disease at high risk for coronary ischaemic 
events.(Hiratzka, Bakris e ta l 2010)
As Pravastatin is a novel potential therapy for treating aortic root pathology in Marfan 
syndrome, the optimal dose is not yet known. The initial dose of 50mg/kg for the murine 
model was chosen due to its effect on cholesterol metabolism in the wild type. Statin dose 
was titrated up until the serum cholesterol dropped by >20%. This occurred at 50mg/kg. This 
was conducted previously by Dr. John Byrne &  Dr. Jonathan McGuinness (personal 
communication). This dose, even though it exceeds a human dose would be considered a bio­
equivalent dose in this murine species. It is the dose required to commence inhibition of the 
H M G  Co-A reductase pathway.
Three groups were considered to assess the optimum dose of Pravastatin, an untreated Marfan 
group, a Marfan group administered 50mg/kg and a Marfan group administered 1 OOmg/kg. 
These groups were compared to the normal group. The 50mg/kg dose was chosen because of 
the effect on cholesterol metabolism and the 1 OOmg/kg to ascertain if there is a dose
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dependent mechanism involved. The aortic root dilatation in the 50mg/kg (Marfan) group 
was reduced by 21%. The aortic root dilatation in the lOOmg/kg (Marfan) group was reduced 
by 33%. An increase in the dose, by a factor of two, increased the effect of the treatment by 
50%. This showed a dose dependent response to treatment with respect to aortic root 
diameter attenuation. However there was no significant difference in aortic wall thickness or 
architecture score with increasing doses. Statins have been shown to reduce the growth rate in 
infra-renal abdominal aortic aneurysms (Schouten, van Laanen et al. 2006) which is 
suggested to have a different mechanism to that of lipid lowering effect of statin therapy. The 
dose response that is observed in the lOOmg/kg group compared to the 50mg/kg group may 
be a dose response that involves the pleiotropic effects of statin therapy involving many 
different mechanisms other than reduction in serum cholesterol. (Wang, Liu et al. 2008) In 
humans the dosage of statins varies between 0 .1 - 1  mg/kg and in rodents dosages vary 
between 1-100 mg/kg and even 500 mg/kg. This is because of a known pharmacodynamic 
resistance to the pharmacological effect in these animals, where higher levels are 
required.(Bjorkhem-Bergman, Lindh et al. 2011)
Due to the variability of phenotypic expression and highly variable genetic mutations 
responsible for Marfan syndrome, patients with Marfan syndrome often present with 
established disease. Patients may have aortic aneurysmal disease and are unaware of both 
their underlying condition and one of the secondary complications of an aneurysmal aorta, 
with or without aortic incompetence (which can lead to heart faiIure).(BakaIli, Bekteshi et al. 
2009) We do not know the effect of treatment of statin therapy or even Losartan therapy in 
the paediatric population. Doxycycline therapy can cause severe dental staining in developing 
dentition in the paediatric population and so is less than an ideal therapy. A small trial was 
conducted with Losartan in a paediatric population and found a reduction in the rate of aortic
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root dilatation.(Brooke, Habashi et a i 2008) To investigate whether a delayed treatment 
strategy would be of benefit with established disease, the timing of Pravastatin administration 
was varied. Normal Pravastatin start time was considered to be 6 weeks of age for the 
purpose of this study. Late start was considered 4 months and very late start considered 5 
months of age. Aortic root diameters were observed to be similar in both late start groups to 
the normal start group at a dose of 50mg/kg. Aortic architectural disruption showed no 
statistical difference in the Marfan groups in which Pravastatin was commenced at different 
time-points. Mean aberrant aortic wall thickening varied, though the variation did not reach 
statistical significance.
Alcian blue staining showed that glycogen deposition within the aortic media, increases in 
Marfan syndrome compared to normal. With Pravastatin treatment in Marfan syndrome, the 
amount of proteoglycan deposition was greatly reduced to normal levels.
Conclusion
In summary, Pravastatin has been shown here to reduce both the growth rate and the overall 
diameter of a normal aorta, with no significant change in the mean aortic wall thickness and 
with preservation of aortic wall architecture. An increased dose of Pravastatin, lOOmg/kg, 
had a statistically significant beneficial effect on the aortic root diameter, with further 
reduction in the aortic root diameter, above that of the 50mg/kg dose. This occurred without a 
change in the aortic architecture or aortic wall thickness. It was observed that administration 
of Pravastatin could be commenced later, with a sustained benefit in attenuation of aortic root 
dilatation.
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Chapter 6 
Discussion
6.1 Discussion
In 1990, it was known that elastic tissues were fragmented and showed disarray in Marfan 
syndrome, with associated accumulation of amorphous matrix between elastic fibres. A 
deficiency of the connective tissue protein fibrillin-1 was noted in the tissue of patients with 
Marfan syndrome. Abnormalities in fibrillin-1 synthesis, secretion and matrix deposition by 
cultured cells of patients were also noted.(Hollister, Godfrey et a l 1990), (Milewicz, Pyeritz 
et a l 1992). Marfan syndrome was found to be caused by mutations in the fibrillin-1 gene 
(FBN1) on chromosome 15.(Kainulainen, Pulkkinen et a l 1990; Dietz, Cutting et a l 1991; 
Dietz, Pyeritz et a l 1991) Early hypotheses of the pathological mechanism in Marfan 
syndrome focused on a structural weakness of the connective tissue due to fibrillin deficiency 
and a consequential failure of elastogenesis. This idea purports that a structural failure is 
bound to occur due to the deficiency of connective tissue. Other features which occur in 
Marfan syndrome such as long bone overgrowth, myxomatous valves, craniofacial 
dysmorphism and reduced muscle mass and reduced fat stores cannot be explained by this 
hypothesis.
It was subsequently discovered that fibrillin-1 was not needed for elastogenesis, though it was 
needed for maintenance of elastic fibres in post-natal life.(Dietz, Cutting et a l 1991; Pereira, 
Andrikopoulos et a l 1997) Elastic fibre breakdown correlated both temporally and spatially 
with a number of predictable events, including elastic fibre calcification, local recruitment of 
inflammatory cells, and increased expression of selected matrix-degrading enzymes (MMP 2 
&  M M P  9) by vascular smooth muscle cells. (Bunton, Biery et a l 2001)
While investigating the pathogenesis of Marfan syndrome using a genetically modified 
munne model of Marfan syndrome, a discovery was made. The lung tissue at birth, in the
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diseased models, showed diffuse widening of the distal air space at birth due to failure of 
septation of the pre-alveolar saccule, with no associated destructive or inflammatory 
changes.(Neptune, Frischmeyer et a l 2003) A deficiency of fibrillin-1 had impeded a signal 
for septation and it was found that this was related to excessive TGF-P activity. On foot of 
this discovery TGF-p inhibition and Losartan became subjects of investigation in Marfan 
syndrome. Losartan has been found to down-regulate the expression of TGF-p receptors Type I 
and II in a model of diabetic nephropathy in rats.(Guo and Qiu 2003) Doxycycline at sub­
antimicrobial doses was noted to have non-specific/broad spectrum matrix metalloproteinase 
inhibitory properties. Matrix metalloproteinase levels in carotid plaques, which were removed 
during carotid endarterectomy, were reduced following Pravastatin therapy.(Crisby, Nordin- 
Fredriksson et a l 2001) This information combined with the fact that matrix 
metalloproteinase levels were elevated in Marfan aortic root aneurysmal tissue, prompted our 
team to investigate Pravastatin for the treatment of aortic root pathology in Marfan syndrome.
The first study was conducted using a murine model of Marfan syndrome and compared the 
natural history of the disease to normal mice. The pattern, timing and extent of the disease in 
relation to a number of physiological, histological and ultra-structural parameters were 
observed.(Chapter 3, Section 3.3) This provided important information to understand the 
pathophysiology of Marfan syndrome. Aortic root diameter and growth rate were found to be 
elevated in Marfan syndrome with associated histological changes (Section 3.3.1), as in other 
studies.(Habashi, Judge et a l 2006) The aneurysmal dilatation was associated with a decrease 
in left ventricular contractility and loss of the aortic dicrotic notch (Section 3.3.2). Aortic 
pulse pressure was not significantly altered. The progressive aortic root dilatation was 
associated with histological changes. These histological changes included, progressive 
aberrant aortic wall thickening and progressive loss of the aortic wall integrity, which was
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similar to studies conducted by Habashi et a l and Chung et a l (Habashi, Judge et a I 2006; 
Chung, Yang et a l 2008) This loss of architectural integrity was accompanied by a reduction 
in the volume of elastin within the aortic media, which was similar to findings by Chung et 
al (Chung, Yang et a l 2008)
Ultra-structural analysis suggested evidence of an increased amount of protein production 
and transportation within the aortic vascular smooth muscle. This was assessed by the 
increased volume of rough Endoplasmic Reticulum within the cell. There was also an 
increased volume of mitochondria located near the rough endoplasmic reticulum. They 
provide energy for the rough endoplasmic reticulum. This increased level of activity of the 
cell organelles was associated with the pathological findings of disruption of the aortic 
medial layer and thickening of this layer, which was similar to a previous study in mice 
homozygous for a targeted hypomorphic allele of fibrillin-1. (Bunton, Biery et a l 2001) 
Aortic root growth rate observed in a group of untreated normal mice was compared to a 
group of normal mice treated with Pravastatin (Section 5.3.1). There was a significant 
reduction in growth rate, from 3 to 8 months, of the aortic root diameter and a small reduction 
in the overall aortic root diameter at 8 months. This was achieved without deleterious side 
effects with regard to aortic wall thickness and architectural integrity (Figures 5.2 and 5.3 in 
Chapter 5). Long term treatment of patient with a statin can improve the aortic stiffness in 
human trials (Kontopoulos, Athyros et a l 2003), though no other study has proven a 
beneficial effect of statin therapy on the aortic root diameter in normal mice.
A study was conducted to assess the optimal dose of Pravastatin in the Marfan groups. Two 
doses, 50mg/kg and lOOmg/kg were compared to an untreated Marfan group. A  dose 
dependent benefit was obtained, (Figure 5.4, Chapter 5) with the optimal dose for attenuating 
the aortic root diameter being lOOmg/kg. Unfortunately, aberrant aortic wall thickening &
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architectural integrity were not improved by statin therapy (Figures 5.5 and 5.6), with either 
dose despite a significant reduction in the diameter of the aortic root.
Aortic root pathology is a silent disease and patients with Marfan syndrome often have 
established aortic root dilatation at the time of diagnosis. It is one of the cardinal features of 
the disease.(Loeys, Dietz et a l 2010) Many studies in relation to potential treatments of 
Marfan syndrome focus on initiation of treatment prior to onset of aortic dilatation.(Chung, 
Yang et al 2008; Xiong, Knispel et al. 2008) To become more clinically relevant, a study 
was conducted to assess aortic root pathology when Pravastatin therapy, given to Marfan 
groups, was delayed. Therapy was initiated with established aortic root dilatation, and so 
given for a shorter duration in total. Interestingly, there was no statistical significant 
difference between the groups with regard to aortic root dilatation, thickness nor architectural 
disruption. This means that despite a later initiation of therapy, and so a shorter duration of 
therapy, a similar benefit was observed with slowing of aortic root dilatation (Chapter 5, 
Figure 5.7). A recent study which also investigated delayed initiation of treatment in 
established aortic aneurysmal disease, needed to use a combination of therapy, both Losartan 
and Doxycycline to achieve a beneficial result.(Yang, Kim et a l 2010)
Pravastatin therapy attenuated dilatation of the aortic root by 33.3% (Chapter 4, Figure 4.3). 
Therapy had no effect on pulse pressure or myocardial contractility. Pravastatin therapy 
preserved elastin volume (Chapter 4, Figure 4.8) and reduced glycogen deposition, though 
showed no benefit in aberrant aortic wall thickening (Chapter 4, Figure 4.6) or architectural 
disruption(Chapter 4, Figure 4.7).
Losartan attenuated dilatation of the aortic root diameter by 33.3% (Chapter 4, Figure 4.3). 
Pravastatin is equipotent to Losartan in attenuation of aortic root dilatation in the murine 
Marfan model. Losartan would be considered by some to be “the gold-standard” for 
investigative therapies for medical treatment of Marfan pathology due to the recent findings
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in Marfan models of disease and its central place in discovery of pathophysiology of Marfan 
syndrome. Losartan in this study normalised aberrant aortic wall thickening and preserved 
elastin volume though had little beneficial effect on architectural disruption (Chapter 4, 
Figure 4.3), which is different to the findings by Habashi et ^ /.(Habashi, Judge et a l 2006) 
The reason for the difference between the two studies is unclear.
Doxycycline showed no benefit in attenuating aortic root dilatation in Marfan syndrome 
(Chapter 4, Figure 4.3). It did not prevent aberrant aortic wall thickness (Chapter 4, Figure 
4.6), in fact it exacerbated it(Chapter 4, Figure 4.7). Doxycycline did not preserve 
architectural structure or elastin volume (Chapter 4, Figure 4.8). Doxycycline’s performance 
was inferior to Losartan and Pravastatin.
Losartan is noted to work by inhibiting TGF-p at the receptor level, before it activates the 
Smad cascade.(Habashi, Judge et a l 2006) This was reflected in the normal volume of rough 
endoplasmic reticulum measured in the aortic vascular smooth muscle cell (Chapter 4, Figure 
4.9). This was associated with many of the beneficial aspects of Losartan. Pravastatin reduced 
the level of rough endoplasmic reticulum in the aortic vascular smooth muscle (Chapter 4, 
Figure 4.9) cell but not as completely as Losartan did. This would suggest that Pravastatin is 
acting by a different mechanism to Losartan. These findings suggest that Pravastatin is acting 
at a post-translational level. Statins do not affect matrix metalloproteinase m R N A  
levels. (Luan, Chase et a l 2003) Statins reduce the ability of the cell to prenylate proteins 
such as matrix metalloproteinases. This corresponds to ultra-structural observations (Chapter 
4, Figures 4.9). Pravastatin reduces the aortic vascular smooth muscle cells’ ability to 
prenylate proteins. These proteins which are excessively produced in Marfan syndrome 
(mainly metal loproteinases), are not prenylated and so the disease process is attenuated. 
Further investigation into the mechanism of action of statin therapy in Marfan syndrome 
could include measuring m R N A  levels for matrix metal loproteinases. These levels could then
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be compared to m R N A  levels for matrix metalloproteinases in Marfan syndrome with 
Losarían therapy and without any intervention. By comparing these measurements, to total 
metalloproteinase levels in the tissue, one could discover more precisely, the mechanism of 
action of statin therapy in Marfan syndrome. Ideally one could measure intra-cellular and 
extra-cellular levels of matrix metalloproteinases. If statins were exerting their beneficial 
effect by inhibiting prénylation alone, a number of results would be suggestive of this. 
Messenger RNA levels for matrix metalloproteinase levels would remain elevated. Intra­
cellular matrix metalloproteinase levels may remain elevated. Tissue or extra-cellular matrix 
metalloproteinase levels would be reduced. To conclude that this was unequivocally related 
to prénylation, if measured, one would expect mevalonate, famesyl pyrophosphate and 
geranylgeranyl pyrophosphate levels to be reduced in Marfan treated with Pravastatin and the 
beneficial effects would be reversed by administration of mevalonate.
The pathogenesis of Marfan syndrome is related to TGF-P activity. This may not be a 
complete summary of events related to the pathogenesis. Different pathways are currently 
being investigated. TGF-p can initiate multiple downstream signalling cascades, including 
both canonical (Smad-dependent) and non-canonical (Smad-independent) pathways.(Derynck 
and Zhang 2003) It is now known that TGF-p induced activation of p38 mitogen activated 
protein kinase is mediated independently of Smads.(Yu, Hebert et a l 2002) Recently, it was 
discovered that TRAF6 is specifically required for the Smad-independent activation of JNK 
and p38 MAP kinase. (Yamashita, Fatyol et al. 2008) Statin therapy may have its effect by 
non-canonical Smad signalling. Statins can decrease JNK phosphorylation and this lead to 
reduced metalloproteinase activity, via blockade of the Rho-A-JNK-c-Jun-MMP2 (Rho- 
A;Ras homolog gene family member A, JNK; c-Jun N-terminal kinases) cascade.(Fromigue, 
Hamidouche et a l 2008) These results show that our knowledge of TGF-p signalling is 
rapidly evolving. So too is our knowledge of potential treatment options and how they
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interact with these pathways. The interaction of TGF-p with other pathways is under active 
investigation. Therefore one cannot relate the pathogenesis of Marfan syndrome purely to 
TGF-p activity. The fact that potentially highly complex molecular signalling is involved in 
normal homeostasis of the extracellular matrix of the aortic wall suggests that there may also 
be highly complex mechanisms involved in dysregulation of homeostasis of the extracellular 
matrix in Marfan syndrome.
As the pathogenesis is more complex than previously anticipated, this would suggest that 
challenges and indeed opportunity lie ahead for research into Marfan syndrome. These 
challenges include understanding both pathogenesis and variable expression of the disease. 
By understanding these more fully, more targets for therapy may be explored. Discovery of 
disease specific biomarkers of both disease activity and response to treatment, will improve 
assessment of prognosis. As discoveries unfold, comprehensive guidelines will need to be 
drawn up, for optimal management of the condition. This should be conducted following 
rigorous assessment of treatment options. This too is a challenge for the medical community 
who are involved in treating Marfan syndrome.
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